



(11)

EP 3 281 952 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
24.06.2020 Bulletin 2020/26

(51) Int Cl.:
C07K 16/18 (2006.01) **C07K 14/54** (2006.01)
A61K 51/10 (2006.01) **A61P 19/00** (2006.01)
A61P 29/00 (2006.01) **A61K 39/00** (2006.01)
A61K 47/68 (2017.01)

(21) Application number: **17189028.8**

(22) Date of filing: **27.10.2008**

(54) **AN ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS**
MIT RHEUMATOIDER ARTHRITIS ASSOZIIERTES ANTIGEN
UN ANTIGÈNE ASSOCIÉ À LA POLYARTHRITE RHUMATOÏDE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: **30.10.2007 US 983606 P**

(43) Date of publication of application:
14.02.2018 Bulletin 2018/07

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
08844563.0 / 2 209 805

(73) Proprietor: **Philogen S.p.A.**
53100 Siena (IT)

(72) Inventors:
• **KASPAR, Manuela**
8093 Zurich (CH)
• **SCHWAGER, Kathrin**
8093 Zurich (CH)
• **TRACHSEL, Eveline**
8093 Zurich (CH)

(74) Representative: **Pfizer**
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 (FR)

(56) References cited:
EP-A- 0 580 859 US-A1- 2006 024 757

- **TRACHSEL EVELINE ET AL:** "Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis", **ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 29 January 2007 (2007-01-29), page R9, XP021026953, ISSN: 1478-6354**
- **HOLT L J ET AL:** "Domain antibodies: proteins for therapy", **TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484-490, XP004467495, ISSN: 0167-7799**
- **DAVIES J ET AL:** "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", **IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169-179, XP004070292, ISSN: 1380-2933**
- **CHEVALIER X ET AL:** "Presence of ED-A containing fibronectin in human articular cartilage from patients with osteoarthritis and rheumatoid arthritis", **JOURNAL OF RHEUMATOLOGY, TORONTO, CA, vol. 23, no. 6, 1 June 1996 (1996-06-01), pages 1022-1030, XP009111633, ISSN: 0315-162X**
- **KRIEGSMANN J ET AL:** "Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis.", **RHEUMATOLOGY INTERNATIONAL JAN 2004, vol. 24, no. 1, January 2004 (2004-01), pages 25-33, XP002517679, ISSN: 0172-8172**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 281 952 B1

- PETERS J H ET AL: "Preferential recognition of a fragment species of osteoarthritic synovial fluid fibronectin by antibodies to the alternatively spliced EIIIA segment.", ARTHRITIS AND RHEUMATISM NOV 2001, vol. 44, no. 11, November 2001 (2001-11), pages 2572-2585, XP002517680, ISSN: 0004-3591
- CLAUDEPIERRE P ET AL: "Increased Ed-B fibronectin plasma levels in spondyloarthropathies: comparison with rheumatoid arthritis patients and a healthy population", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 38, 1 January 1999 (1999-01-01), pages 1099-1103, XP002207493, ISSN: 1462-0324
- LIAO YUNG-FENG ET AL: "The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 26 APR 2002, vol. 277, no. 17, 26 April 2002 (2002-04-26), pages 14467-14474, XP002517681, ISSN: 0021-9258
- OKAMURA Y ET AL: "The extra domain A of fibronectin activates Toll-like receptor 4", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BIRMINGHAM, US, vol. 276, no. 13, 30 March 2001 (2001-03-30), pages 10229-10233, XP003008523, ISSN: 0021-9258

Description

[0001] The present disclosure relates to the detection and treatment of rheumatoid arthritis (RA). The invention involves use of a binding member that binds the ED-A isoform of fibronectin, especially a binding member that binds domain ED-A of fibronectin.

[0002] Rheumatoid arthritis (RA) is a chronic inflammatory and destructive joint disease that affects 0.5-1% of the population in the industrialized world and commonly leads to significant disability and a consequent reduction in quality of life.

[0003] Angiogenesis in the synovial membrane of patients with RA is considered to be an important early step in pathogenesis and in the perpetuation of disease (Taylor, 2002). As in neoplastic disease, angiogenesis feeds the expanding synovium (Walsh et al., 1998). Blood vessel growth probably contributes to the proliferation of the inflammatory synovial pannus as well as to the ingress of inflammatory leukocytes into the synovial tissue. Synovium of patients with RA contained increased amounts of fibroblast growth factor-2 (FGF-2) and of vascular endothelial growth factor (VEGF) (Koch, 2003). Serum VEGF concentrations correlate with disease activity and fall, when synovitis is successfully suppressed by therapy (Taylor, 2002).

[0004] Fibronectin (FN) is a glycoprotein and is widely expressed in a variety of normal tissues and body fluids. It is a component of the extracellular matrix (ECM), and plays a role in many biological processes, including cellular adhesion, cellular migration, haemostasis, thrombosis, wound healing, tissue differentiation and oncogenic transformation.

[0005] Different FN isoforms are generated by alternative splicing of three regions (ED-A, ED-B, IIIICS) of the primary transcript FN pre-mRNA, a process that is modulated by cytokines and extracellular pH (Balza 1988; Carnemolla 1989; Borsi 1990; Borsi 1995). Fibronectin contains two type-III globular extra-domains which may undergo alternative splicing: ED-A and ED-B (French-Constant 1995, Hynes 1990, Kaspar et al. 2006). The ED-As of mouse fibronectin and human fibronectin are 96.7% identical (only 3 amino acids differ between the two 90 amino acid sequences, see Figure 2).

[0006] Expression of the ED-A of fibronectin has been reported in tumour cells and in solid tumours at the mRNA level in breast cancer (Jacobs et al. 2002, Matsumoto et al. 1999) and liver cancer (Oyama et al. 1989, Tavian et al. 1994) and at the level of isolated protein in fibrosarcoma, rhabdomyosarcoma and melanoma (Borsi et al. 1987).

[0007] At the immunohistochemical level, the presence of ED-A has been detected in the extracellular matrix (ECM) of odontogenic tumours (Heikinheimo et al. 1991) and hepatocellular carcinoma (Koukoulis et al. 1995). In contrast, ED-A has been detected in the stroma of malignant breast neoplasms (Koukoulis et al. 1993), and in the blood vessels and basement membranes of well-differentiated renal cell carcinoma (Lohi et al. 1995). However, in less-differentiated renal cell carcinoma (Lohi et al. 1995) and papillary carcinoma of the thyroid (Scarpino et al. 1999) ED-A has been detected in the blood vessels, basement membranes and tumour stroma. The presence of ED-A in the vasculature of gliomas has also been reported (Borsi et al. 1998). Thus, the pattern of ED-A expression reported for different types of tumours is highly variable.

[0008] Antibody-based targeted delivery of bioactive agents to sites of angiogenesis is an attractive therapeutic strategy for cancer treatment, but is largely unexplored for chronic inflammatory diseases. We have previously demonstrated that the ED-B domain of fibronectin, a marker of angiogenesis, is expressed in psoriatic lesions in patients and in a mouse model of psoriasis as well as in arthritic paws in the collagen-induced mouse model of rheumatoid arthritis. Using both radioactive and fluorescent techniques, the human monoclonal antibody L19, specific to EDB, was found to selectively localize at sites of inflammation *in vivo*, following intravenous administration. These results suggest a therapeutic potential for the L19-based selective delivery of bioactive compounds to sites of inflammation (Trachsel, 2007; PCT/EP2007/004044).

[0009] It has been shown before by in-situ-hybridisation that other than ED-B also the ED-A domain of fibronectin can be present in human arthritic specimens (Berndt et al., 1998; Kriegsmann et al., 2004).

[0010] We show herein that anti-EDA antibody, such as the F8 antibody disclosed herein, is able to give a stronger staining pattern on human arthritic specimens compared with the anti-EDB-antibody L19 and the anti-tenascin-C antibodies F16 and G11.

[0011] Furthermore, using both radioactive and fluorescent techniques, the human monoclonal antibody F8, specific to ED-A, was found to selectively localize at sites of inflammation *in vivo*, following intravenous administration.

[0012] Accordingly, ED-A of fibronectin is indicated as a vascular marker of rheumatoid arthritis.

[0013] The present invention is as stated in the claims, in particular the present invention relates to the following particular aspects:

According to a first aspect the invention provides an antibody conjugate for use in a method of treating rheumatoid arthritis in a patient, wherein the antibody conjugate comprises an antibody, or antigen-binding fragment thereof, which binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to a molecule having anti-inflammatory activity, wherein the antibody or antigen-binding fragment comprises a VH domain and a VL domain, wherein; said VH domain comprises a framework and a set of heavy chain complementarity determining regions HCDR1,

EP 3 281 952 B1

HCDR2 and HCDR3, wherein HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 83, 4 and 5, respectively; and
said VL domain comprises a framework and a set of light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 86, 7 and 8, respectively.

[0014] According to a second aspect the invention provides an antibody conjugate for use in a method of delivering a molecule having anti-inflammatory activity to sites of rheumatoid arthritis in a patient, wherein the antibody conjugate comprises an antibody, or antigen-binding fragment thereof, which binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to a molecule having anti-inflammatory activity, wherein the antibody or antigen-binding fragment comprises a VH domain and a VL domain, wherein said VH domain comprises a framework and a set of heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 83, 4 and 5, respectively; and
said VL domain comprises a framework and a set of light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 86, 7 and 8, respectively.

[0015] The invention also provides an antibody conjugate for use according to the first and second aspects, wherein

(a) said VH domain comprises:

- (i) the amino acid sequence of SEQ ID NO: 81; or
- (ii) the amino acid sequence of SEQ ID NO: 81, wherein the amino acid at position 5 of SEQ ID NO: 81 is a leucine residue (L) rather than a valine residue (V); and

b) said VL domain comprises:

- (i) the amino acid sequence of SEQ ID NO: 82;
- (ii) the amino acid sequence of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K);
- (iii) amino acid residues 1-108 of SEQ ID NO: 82; or
- (iv) amino acid residues 1-108 of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K); optionally wherein said VH domain comprises the amino acid sequence of SEQ ID NO: 81, wherein the amino acid at position 5 of SEQ ID NO: 81 is a leucine residue (L) rather than a valine residue (V); and said VL domain comprises amino acid residues 1-108 of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K).

[0016] The invention also provides an antibody conjugate for use according to the first and second aspects, wherein the antibody conjugate comprises:

(i) an antigen-binding fragment of an antibody which binds the Extra Domain A (ED-A) of fibronectin, wherein the antigen-binding fragment comprises a scFv or is a diabody, said antigen-binding fragment comprising:

a) a VH domain consisting of:

- (i) the amino acid sequence of SEQ ID NO: 81; or
- (ii) the amino acid sequence of SEQ ID NO: 81, wherein the amino acid at position 5 of SEQ ID NO: 81 is a leucine residue (L) rather than a valine residue (V); and

b) a VL domain consisting of:

- (i) the amino acid sequence of SEQ ID NO: 82;
- (ii) the amino acid sequence of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K);
- (iii) amino acid residues 1-108 of SEQ ID NO: 82; or
- (iv) amino acid residues 1-108 of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K); and

wherein said VH domain is conjugated to said VL domain via a 5 amino acid linker; and

(ii) human interleukin-10 (IL-10),

5 wherein said VL domain of said antigen-binding fragment is conjugated to said human IL-10 via a peptide linker consisting of the amino acid sequence (SSSSG)₃.

[0017] Binding molecules such as antibody molecules that bind the A-FN and/or the ED-A of fibronectin represent novel agents which may be used for the preparation of a medicament for the treatment of rheumatoid arthritis (RA).

10 **[0018]** This invention provides the use of a binding member, e.g. an antibody molecule, that binds the Extra Domain-A (ED-A) isoform of fibronectin (A-FN), for the preparation of a medicament for the treatment of rheumatoid arthritis. The invention also provides the use of a binding member, e.g. an antibody molecule, that binds the ED-A of fibronectin for the preparation of a medicament for the treatment of rheumatoid arthritis.

15 **[0019]** The disclosure further provides the use of a binding member, e.g. an antibody molecule, that binds the ED-A isoform of fibronectin for delivery, to sites of rheumatoid arthritis, of a molecule conjugated to the binding member. The disclosure also provides the use of a binding member, e.g. an antibody molecule, that binds the ED-A of fibronectin for delivery, to sites of rheumatoid arthritis, of a molecule conjugated to the binding member. The binding member may be used for the manufacture of a medicament for delivery of such a molecule.

20 **[0020]** The disclosure provides the use of a binding member, e.g. an antibody molecule, that binds the ED-A isoform of fibronectin for the manufacture of a diagnostic product for use in diagnosing rheumatoid arthritis. The disclosure also provides the use of a binding member, e.g. an antibody molecule, that binds the ED-A of fibronectin for the manufacture of a diagnostic product for use in diagnosing rheumatoid arthritis.

[0021] The disclosure further provides a method of detecting or diagnosing rheumatoid arthritis in a human or animal comprising:

- 25 (a) administering to the human or animal a binding member, e.g. an antibody molecule, which binds the ED-A of fibronectin, and
 (b) determining the presence or absence of the binding member in sites of rheumatoid arthritis of the human or animal body;

30 wherein localisation of the binding member to sites of rheumatoid arthritis indicates the presence of rheumatoid arthritis.

[0022] The present disclosure provides a method of treating rheumatoid arthritis in an individual comprising administering to the individual a therapeutically effective amount of a medicament comprising a binding member, e.g. an antibody molecule, which binds the ED-A isoform of fibronectin. The present disclosure also provides a method of treating rheumatoid arthritis in an individual comprising administering to the individual a therapeutically effective amount of a medicament comprising a binding member, e.g. an antibody molecule, which binds the ED-A of fibronectin.

35 **[0023]** The present disclosure provides a composition comprising a binding member, e.g. an antibody molecule, which binds the ED-A isoform of fibronectin, for use in a method of treating rheumatoid arthritis in an individual comprising administering to the individual a therapeutically effective amount of a medicament comprising a binding member, e.g. an antibody molecule, which binds the ED-A isoform of fibronectin. The present disclosure also provides a composition comprising a binding member, e.g. an antibody molecule, which binds the ED-A of fibronectin, for use in a method of treating rheumatoid arthritis in an individual comprising administering to the individual a therapeutically effective amount of a medicament comprising a binding member, e.g. an antibody molecule, which binds the ED-A of fibronectin.

40 **[0024]** The disclosure provides a method of delivering a molecule to the neovasculature of sites of rheumatoid arthritis in a human or animal comprising administering to the human or animal a binding member, e.g. an antibody molecule, which binds the ED-A isoform of fibronectin, wherein the binding member is conjugated to the molecule. The disclosure also provides a method of delivering a molecule to the neovasculature of sites of rheumatoid arthritis in a human or animal comprising administering to the human or animal a binding member, e.g. an antibody molecule which binds the ED-A of fibronectin, wherein the binding member is conjugated to the molecule.

45 **[0025]** A binding member for use in the invention may be an antibody which binds the ED-A isoform of fibronectin and/or the ED-A of fibronectin, comprising one or more complementarity determining regions (CDRs) of antibody H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9, or variants thereof. Preferably, a binding member for use in the invention is an antibody which binds the ED-A isoform of fibronectin and/or the ED-A of fibronectin, comprising one or more complementarity determining regions (CDRs) of antibody B2, C5, D5, C8, F8, B7 or G9, or variants thereof. Most preferably, a binding member for use in the invention is an antibody which binds the ED-A isoform of fibronectin and/or the ED-A of fibronectin, comprising one or more complementarity determining regions (CDRs) of antibody F8 or variants thereof.

50 **[0026]** A binding member for use in the invention may comprise a set of H and/or L CDRs of antibody H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9, or a set of H and/or L CDRs of antibody H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9 with ten or fewer, e.g. one, two, three, four, or five, amino acid substitutions within the disclosed set of H and/or L CDRs.

Preferably, a binding member for use in the invention comprises a set of H and/or L CDRs of antibody B2, C5, D5, C8, F8, B7 or G9 with ten or fewer, e.g. one, two, three, four, or five, amino acid substitutions within the disclosed set of H and/or L CDRs. Preferably, a binding member for use in the invention comprises a set of H and/or L CDRs of antibody F8 with ten or fewer, e.g. one, two, three, four, or five, amino acid substitutions within the disclosed set of H and/or L CDRs.

[0027] Substitutions may potentially be made at any residue within the set of CDRs, and may be within CDR1, CDR2 and/or CDR3.

[0028] For example, a binding member for use in the invention may comprise one or more CDRs as described herein, e.g. a CDR3, and optionally also a CDR1 and CDR2 to form a set of CDRs.

[0029] A binding member for use in the invention may also comprise an antibody molecule, e.g. a human antibody molecule. The binding member normally comprises an antibody VH and/or VL domain. VH domains of binding members are also provided for use in the invention. Within each of the VH and VL domains are complementarity determining regions, ("CDRs"), and framework regions, ("FRs"). A VH domain comprises a set of HCDRs, and a VL domain comprises a set of LCDRs. An antibody molecule may comprise an antibody VH domain comprising a VH CDR1, CDR2 and CDR3 and a framework. It may alternatively or also comprise an antibody VL domain comprising a VL CDR1, CDR2 and CDR3 and a framework. The VH and VL domains and CDRs of antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 and G9 are described herein. All VH and VL sequences, CDR sequences, sets of CDRs and sets of HCDRs and sets of LCDRs disclosed herein represent embodiments of a binding member for use in the invention. As described herein, a "set of CDRs" comprises CDR1, CDR2 and CDR3. Thus, a set of HCDRs refers to HCDR1, HCDR2 and HCDR3, and a set of LCDRs refers to LCDR1, LCDR2 and LCDR3. Unless otherwise stated, a "set of CDRs" includes HCDRs and LCDRs.

[0030] A binding member for use in the invention may comprise an antibody VH domain comprising complementarity determining regions HCDR1, HCDR2 and HCDR3 and a framework, wherein as disclosed HCDR1 is SEQ ID NO: 3, 23, 33, 43, 53, 63, 73, according to the invention 83, as disclosed 93, 103 or 113, and according to the invention wherein optionally HCDR2 is SEQ ID NO: 4 and/or HCDR3 is SEQ ID NO: 5. Preferably, as disclosed the HCDR1 is SEQ ID NO: 23, 33, 43, 53, 73, 83 or 103. Most preferably, according to the invention the HCDR1 is SEQ ID NO: 83.

[0031] Typically, a VH domain is paired with a VL domain to provide an antibody antigen-binding site, although as discussed further below a VH or VL domain alone may be used to bind antigen. Thus, a binding member for use in the invention may further comprise an antibody VL domain comprising complementarity determining regions LCDR1, LCDR2 and LCDR3 and a framework, wherein as disclosed LCDR1 is SEQ ID NO: 6, 26, 36, 46, 56, 66, 76, according to the invention 86, as disclosed 96, 106 or 116 and wherein according to the invention optionally LCDR2 is SEQ ID NO: 7 and/or LCDR3 is SEQ ID NO: 8. Preferably, as disclosed the LCDR1 is SEQ ID NO: 26, 36, 46, 56, 76, 86 or 106. Most preferably, according to the invention the LCDR1 is SEQ ID NO: 86.

[0032] A binding member for use in the invention may be an isolated antibody molecule for the ED-A of fibronectin, comprising a VH domain and a VL domain, wherein the VH domain comprises a framework and a set of complementarity determining regions HCDR1, HCDR2 and HCDR3 and wherein the VL domain comprises complementarity determining regions LCDR1, LCDR2 and LCDR3 and a framework, and wherein

HCDR1 as disclosed has amino acid sequence SEQ ID NO: 3, 23, 33, 43, 53, 63, 73, according to the invention 83, as disclosed 93, 103 or 113,

HCDR2 has amino acid sequence SEQ ID NO: 4,

HCDR3 has amino acid sequence SEQ ID NO: 5,

LCDR1 has amino acid sequence as disclosed SEQ ID NO: 6, 26, 36, 46, 56, 66, 76, according to the invention 86, as disclosed 96, 106 or 116;

LCDR2 has according to the invention amino acid sequence SEQ ID NO: 7; and

LCDR3 has according to the invention amino acid sequence SEQ ID NO: 8.

[0033] One or more CDRs or a set of CDRs of an antibody may be grafted into a framework (e.g. human framework) to provide an antibody molecule for use in the invention. Framework regions may comprise human germline gene segment sequences. Thus, the framework may be germlined, whereby one or more residues within the framework are changed to match the residues at the equivalent position in the most similar human germline framework. A binding member for use in the invention may be an isolated antibody molecule having a VH domain comprising a set of HCDRs in a human germline framework, e.g. DP47. Normally the binding member also has a VL domain comprising a set of LCDRs, e.g. in a human germline framework. The human germline framework of the VL domain may be DPK22.

[0034] A VH domain for use in the invention may have amino acid sequence as disclosed SEQ ID NO: 1, 21, 31, 41, 51, 61, 71, according to the invention 81, as disclosed 91, 101 or 111. Preferably, a VH domain for use in the invention has amino acid sequence as disclosed SEQ ID NO: 21, 31, 41, 51, 71, according to the invention 81 or as disclosed 101. Most preferably, a VH domain for use in the invention has amino acid sequence according to the invention SEQ ID NO: 81. A VL domain for use in the invention may have the amino acid as disclosed SEQ ID NO: 2, 22, 32, 42, 52, 62, 72, according to the invention 82, as disclosed 92, 102 or 112. Preferably, a VL domain for use in the invention has amino acid as disclosed SEQ ID NO: 22, 32, 42, 52, 72, according to the invention 82 or as disclosed 102. Most preferably, a VL domain for use in the invention has amino acid according to the invention SEQ ID NO: 82.

[0035] A binding member for use in the invention may be or comprise a single chain Fv (scFv), comprising a VH domain and a VL domain joined via a peptide linker. The skilled person may select an appropriate length and sequence of linker, e.g. at least 5 or 10 amino acids in length, up to about 15, 20 or 25 amino acids in length. The linker may have the amino acid sequence GSSGG (SEQ ID NO: 28). The scFv may consist of or comprise amino acid sequence SEQ ID NO: 9.

[0036] A single chain Fv (scFv) may be comprised within a mini-immunoglobulin or small immunoprotein (SIP), e.g. as described in (Li et al., 1997). A sip may comprise an scFv molecule fused to the CH4 domain of the human IgE secretory isoform IgE-S2 (ϵ_{S2} -CH4; Batista et al., 1996) forming an homo-dimeric mini-immunoglobulin antibody molecule.

[0037] Alternatively, a binding member for use in the disclosure may comprise an antigen-binding site within a non-antibody molecule, normally provided by one or more CDRs e.g. a set of CDRs in a non-antibody protein scaffold. Binding members, including non-antibody and antibody molecules, are described in more detail elsewhere herein.

[0038] A binding member for use in the disclosure may be conjugated to a molecule that has biocidal, cytotoxic immunosuppressive or anti-inflammatory activity. Interleukin-10 is an advantageous molecule for conjugation with a binding member in accordance with the present invention, and useful in treatment of rheumatoid arthritis. Furthermore, a binding member for use in the disclosure may be conjugated to a radioisotope, a detectable label or a photosensitizer.

[0039] These and other aspects of the invention are described in further detail below.

BRIEF DESCRIPTION OF THE FIGURES

[0040]

Figure 1 shows the results of immunohistochemistry on human arthritic specimens using antibodies directed to markers of angiogenesis. Darker staining indicates strong expression of the antigen, visualized by white arrows. F8 is an antibody molecule that binds ED-A, disclosed herein, L19 is an antibody molecule that binds ED-B (e.g. Pini et al. 1998), F16 and G11 are antibody molecules that bind Tenascin-C domains A1 and C, respectively (WO2006/050834).

Figure 2 shows the results of immunofluorescence analysis on human arthritic specimens using the F8 antibody molecule directed against the ED-A domain of fibronectin. White staining indicates strong expression of the antigen.

Figure 3 shows an alignment between A: the human ED-A (top sequence) and B: the mouse ED-A (bottom sequence). The asterisks indicate the amino acid positions where the amino acids of the human ED-A and the mouse ED-A are identical.

Figure 4A shows the nucleotide sequence of the anti-ED-A antibody H1 heavy chain (VH) (SEQ ID NO: 12). The nucleotide sequence of the heavy chain CDR1 of anti-ED-A antibody H1 is underlined. The nucleotide sequence of the heavy chain CDR2 of the anti-ED-A antibody H1 is shown in *italics and underlined*. The nucleotide sequence of the heavy chain CDR3 of anti-ED-A antibody H1 is shown in **bold and underlined**.

Figure 4B shows the nucleotide sequence of the anti-ED-A antibody H1 linker sequence (SEQ ID NO: 14).

Figure 4C shows the nucleotide sequence of the anti-ED-A antibody H1 light chain (VL) (SEQ ID NO: 13). The nucleotide sequence of the light chain CDR1 of anti-ED-A antibody H1 is underlined. The nucleotide sequence of the light chain CDR2 of the anti-ED-A antibody H1 is shown in *italics and underlined*. The nucleotide sequence of the light chain CDR3 of anti-ED-A antibody H1 is shown in **bold and underlined**.

Figure 5A shows the amino acid sequence of the anti-ED-A antibody H1 heavy chain (VH) (SEQ ID NO: 1). The amino acid sequence of the heavy chain CDR1 (SEQ ID NO: 3) of anti-ED-A antibody H1 is underlined. The amino acid sequence of the heavy chain CDR2 (SEQ ID NO: 4) of the anti-ED-A antibody H1 is shown in *italics and underlined*. The amino acid sequence of the heavy chain CDR3 (SEQ ID NO: 5) of anti-ED-A antibody H1 is shown in **bold and underlined**. Figure 5B shows the amino acid sequence of the anti-ED-A antibody H1 linker sequence (SEQ ID NO: 11).

Figure 5C shows the amino acid sequence of the anti-ED-A antibody H1 light chain (VL) (SEQ ID NO: 2). The amino acid sequence of the light chain CDR1 (SEQ ID NO: 6) of anti-ED-A antibody H1 is underlined. The amino acid sequence of the light chain CDR2 (SEQ ID NO: 7) of the anti-ED-A antibody H1 is shown in *italics and underlined*. The amino acid sequence of the light chain CDR3 (SEQ ID NO: 8) of anti-ED-A antibody H1 is shown in **bold and underlined**.

Figure 6 shows the sequence of a nucleic acid construct including a coding sequence for F8-IL10. The structure is HINDIII Secretion sequence F8 (14aa linker) linker(SSSSG)₃-IL10-Stop-NotI, as follows: a HINDIII restriction site is underlined, sequence encoding the secretion signal is in *italics*, the F8 VH-encoding sequence is in **bold** following the secretion signal sequence, sequence encoding the 14 amino acid linker is in lower case, F8 VL-encoding sequence is in **bold** following the 14 amino acid linker sequence, a linker (SSSSG)₃ sequence follows the F8 encoding sequence underlined and in italics, the IL-10 encoding sequence is double-underlined; stop is then in lower case, followed by a NOTI restriction site that is underlined.

Figure 7 shows the amino acid sequence of an antibody scFv (F8) IL-10 conjugate, including linkers, of structure: VH-linker-VL-linker-IL-10. The VH and VL domains are in **bold**, the scFv linker is in lower case, the linker between scFv and IL10 is in lower case and *italics*, the IL-10 sequence is underlined.

Figure 8 illustrates cloning, expression and purification of F8-IL10 and HyHel10-IL10:

Figure 8a shows a schematic representation of a pcDNA3.1 vector containing the elements of the F8-IL10 fusion proteins. The human IL10 moiety was fused to the C-terminus of the scFv antibody fragment by the 15 amino acid linker (SSSSG)₃. The secretion sequence at the N-terminus is required for secretion of recombinant proteins.

Figure 8b shows the results of SDS-PAGE analysis of purified fusion proteins: Lane 1, molecular weight marker; lanes 2 & 3, F8-IL10 under non-reducing and reducing conditions. The monomeric fusion protein is expected to have a molecular weight of 46 kDa.

Figure 8c shows a size exclusion chromatography profile of purified F8-IL10 (Superdex 200). The peak eluting at 13 ml retention volume corresponds to the non-covalent homodimeric form of F8-IL10, the smaller peak eluting at 14 ml retention volume corresponds to the monomeric fraction.

Figure 8d shows the results of an activity assay of F8-IL10. The activity of F8-IL10 was compared with that of recombinant human IL10 on MC/9 cells.

TERMINOLOGY

Fibronectin

[0041] Fibronectin is an antigen subject to alternative splicing, and a number of alternative isoforms of fibronectin are known, as described elsewhere herein. Extra Domain-A (EDA or ED-A) is also known as ED, extra type III repeat A (EIIIA) or EDI. The sequence of human ED-A has been published by Kornblihtt et al. (1984), *Nucleic Acids Res.* 12, 5853-5868 and Paoletta et al. (1988), *Nucleic Acids Res.* 16, 3545-3557. The sequence of human ED-A is also available on the SwissProt database as amino acids 1631-1720 (Fibronectin type-III 12; extra domain 2) of the amino acid sequence deposited under accession number P02751. The sequence of mouse ED-A is available on the SwissProt database as amino acids 1721-1810 (Fibronectin type-III 13; extra domain 2) of the amino acid sequence deposited under accession number P11276.

[0042] The ED-A isoform of fibronectin (A-FN) contains the Extra Domain-A (ED-A). The sequence of the human A-FN can be deduced from the corresponding human fibronectin precursor sequence which is available on the SwissProt database under accession number P02751. The sequence of the mouse A-FN can be deduced from the corresponding mouse fibronectin precursor sequence which is available on the SwissProt database under accession number P11276. The A-FN may be the human ED-A isoform of fibronectin. The ED-A may be the Extra Domain-A of human fibronectin.

[0043] ED-A is a 90 amino acid sequence which is inserted into fibronectin (FN) by alternative splicing and is located between domain 11 and 12 of FN (Borsi et al., 1987, *J. Cell Biol.*, 104, 595-600). ED-A is mainly absent in the plasma form of FN but is abundant during embryogenesis, tissue remodelling, fibrosis, cardiac transplantation and solid tumour growth.

Alternative splicing

[0044] Alternative splicing refers to the occurrence of different patterns of splicing of a primary RNA transcript of DNA to produce different mRNAs. After excision of introns, selection may determine which exons are spliced together to form the mRNA. Alternative splicing leads to production of different isoforms containing different exons and/or different numbers of exons. For example one isoform may comprise an additional amino acid sequence corresponding to one or more exons, which may comprise one or more domains.

Binding member

[0045] This describes one member of a pair of molecules that bind one another. The members of a binding pair may be naturally derived or wholly or partially synthetically produced. One member of the pair of molecules has an area on its surface, or a cavity, which binds to and is therefore complementary to a particular spatial and polar organization of the other member of the pair of molecules. Examples of types of binding pairs are antigen-antibody, biotin-avidin, hormone-hormone receptor, receptor-ligand, enzyme-substrate. The present disclosure is concerned with antigen-antibody type reactions.

[0046] A binding member normally comprises a molecule having an antigen-binding site. For example, a binding member may be an antibody molecule or a non-antibody protein that comprises an antigen-binding site.

[0047] An antigen binding site may be provided by means of arrangement of complementarity determining regions (CDRs) on non-antibody protein scaffolds such as fibronectin or cytochrome B etc. (Haan & Maggos, 2004; Koide 1998;

Nygren 1997), or by randomising or mutating amino acid residues of a loop within a protein scaffold to confer binding specificity for a desired target. Scaffolds for engineering novel binding sites in proteins have been reviewed in detail by Nygren et al. (1997). Protein scaffolds for antibody mimics are disclosed in WO/0034784, in which the inventors describe proteins (antibody mimics) that include a fibronectin type III domain having at least one randomised loop. A suitable scaffold into which to graft one or more CDRs, e.g. a set of HCDRs, may be provided by any domain member of the immunoglobulin gene superfamily. The scaffold may be a human or non-human protein. An advantage of a non-antibody protein scaffold is that it may provide an antigen-binding site in a scaffold molecule that is smaller and/or easier to manufacture than at least some antibody molecules. Small size of a binding member may confer useful physiological properties such as an ability to enter cells, penetrate deep into tissues or reach targets within other structures, or to bind within protein cavities of the target antigen. Use of antigen binding sites in non-antibody protein scaffolds is reviewed in Wess, 2004. Typical are proteins having a stable backbone and one or more variable loops, in which the amino acid sequence of the loop or loops is specifically or randomly mutated to create an antigen-binding site that binds the target antigen. Such proteins include the IgG-binding domains of protein A from *S. aureus*, transferrin, tetranectin, fibronectin (e.g. 10th fibronectin type III domain) and lipocalins. Other approaches include synthetic "Microbodies" (Selecore GmbH), which are based on cyclotides - small proteins having intra-molecular disulphide bonds.

[0048] In addition to antibody sequences and/or an antigen-binding site, a binding member for use in the present disclosure may comprise other amino acids, e.g. forming a peptide or polypeptide, such as a folded domain, or to impart to the molecule another functional characteristic in addition to ability to bind antigen. Binding members for use in the disclosure may carry a detectable label, or may be conjugated to a toxin or a targeting moiety or enzyme (e.g. via a peptidyl bond or linker). For example, a binding member may comprise a catalytic site (e.g. in an enzyme domain) as well as an antigen binding site, wherein the antigen binding site binds to the antigen and thus targets the catalytic site to the antigen. The catalytic site may inhibit biological function of the antigen, e.g. by cleavage.

[0049] Although, as noted, CDRs can be carried by non-antibody scaffolds, the structure for carrying a CDR or a set of CDRs will generally be an antibody heavy or light chain sequence or substantial portion thereof in which the CDR or set of CDRs is located at a location corresponding to the CDR or set of CDRs of naturally occurring VH and VL antibody variable domains encoded by rearranged immunoglobulin genes. The structures and locations of immunoglobulin variable domains may be determined by reference to Kabat 1987, and updates thereof, now available on the Internet (at immunobme.nwu.edu or find "Kabat" using any search engine). By CDR region or CDR, it is intended to indicate the hyper-variable regions of the heavy and light chains of the immunoglobulin as defined by Kabat et al. (1987), (Kabat 1991a, and later editions). An antibody typically contains 3 heavy chain CDRs and 3 light chain CDRs. The term CDR or CDRs is used here in order to indicate, according to the case, one of these regions or several, or even the whole, of these regions which contain the majority of the amino acid residues responsible for the binding by affinity of the antibody for the antigen or the epitope which it recognizes.

[0050] Among the six short CDR sequences, the third CDR of the heavy chain (HCDR3) has a greater size variability (greater diversity essentially due to the mechanisms of arrangement of the genes which give rise to it). It can be as short as 2 amino acids although the longest size known is 26. Functionally, HCDR3 plays a role in part in the determination of the specificity of the antibody (Segal 1974; Amit 1986; Chothia 1987; Chothia 1989; Caton 1990; Sharon 1990a; Sharon 1990b; Kabat et al., 1991b).

Antibody Molecule

[0051] This describes an immunoglobulin whether natural or partly or wholly synthetically produced. The term also relates to any polypeptide or protein comprising an antibody antigen-binding site. It must be understood here that the invention does not relate to the antibodies in natural form, that is to say they are not in their natural environment but that they have been able to be isolated or obtained by purification from natural sources, or else obtained by genetic recombination, or by chemical synthesis, and that they can then contain unnatural amino acids as will be described later. Antibody fragments that comprise an antibody antigen-binding site include, but are not limited to, antibody molecules such as Fab, Fab', Fab'-SH, scFv, Fv, dAb, Fd; and diabodies.

[0052] It is possible to take monoclonal and other antibodies and use techniques of recombinant DNA technology to produce other antibodies or chimeric molecules that bind the target antigen. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the CDRs, of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB 2188638A or EP-A-239400, and a large body of subsequent literature. A hybridoma or other cell producing an antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.

[0053] As antibodies can be modified in a number of ways, the term "antibody molecule" should be construed as covering any binding member or substance having an antibody antigen-binding site with the required specificity and/or binding to antigen. Thus, this term covers antibody fragments and derivatives, including any polypeptide comprising an antibody antigen-binding site, whether natural or wholly or partially synthetic. Chimeric molecules comprising an antibody

antigen-binding site, or equivalent, fused to another polypeptide (e.g. derived from another species or belonging to another antibody class or subclass) are therefore included. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023, and a large body of subsequent literature.

5 [0054] Further techniques available in the art of antibody engineering have made it possible to isolate human and humanised antibodies. For example, human hybridomas can be made as described by Kontermann & Dubel (2001). Phage display, another established technique for generating binding members has been described in detail in many publications such as WO92/01047 (discussed further below) and US patents US5969108, US5565332, US5733743, US5858657, US5871907, US5872215, US5885793, US5962255, US6140471, US6172197, US6225447, US6291650, US6492160, US6521404 and Kontermann & Dubel (2001). Transgenic mice in which the mouse antibody genes are inactivated and functionally replaced with human antibody genes while leaving intact other components of the mouse immune system, can be used for isolating human antibodies (Mendez 1997).

10 [0055] Synthetic antibody molecules may be created by expression from genes generated by means of oligonucleotides synthesized and assembled within suitable expression vectors, for example as described by Knappik et al. (2000) or Krebs et al. (2001).

15 [0056] It has been shown that fragments of a whole antibody can perform the function of binding antigens. Examples of binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CH1 domains; (ii) the Fd fragment consisting of the VH and CH1 domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward 1989; McCafferty 1990; Holt 2003), which consists of a VH or a VL domain; (v) isolated CDR regions; (vi) F(ab')₂ fragments, a bivalent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site (Bird 1988; Huston 1988); (viii) bispecific single chain Fv dimers (PCT/US92/09965) and (ix) "diabodies", multivalent or multispecific fragments constructed by gene fusion (WO94/13804; Holliger 1993a). Fv, scFv or diabody molecules may be stabilized by the incorporation of disulphide bridges linking the VH and VL domains (Reiter 1996). Minibodies comprising a scFv joined to a CH3 domain may also be made (Hu 1996). Other examples of binding fragments are Fab', which differs from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region, and Fab'-SH, which is a Fab' fragment in which the cysteine residue(s) of the constant domains bear a free thiol group.

20 [0057] Antibody fragments for use in the disclosure can be obtained starting from any of the antibody molecules described herein, e.g. antibody molecules comprising VH and/or VL domains or CDRs of any of antibodies described herein, by methods such as digestion by enzymes, such as pepsin or papain and/or by cleavage of the disulfide bridges by chemical reduction. In another manner, antibody fragments of the present invention may be obtained by techniques of genetic recombination likewise well known to the person skilled in the art or else by peptide synthesis by means of, for example, automatic peptide synthesizers such as those supplied by the company Applied Biosystems, etc., or by nucleic acid synthesis and expression.

25 [0058] Functional antibody fragments according to the present disclosure include any functional fragment whose half-life is increased by a chemical modification, especially by PEGylation, or by incorporation in a liposome.

30 [0059] A dAb (domain antibody) is a small monomeric antigen-binding fragment of an antibody, namely the variable region of an antibody heavy or light chain (Holt 2003). VH dAbs occur naturally in camelids (e.g. camel, llama) and may be produced by immunizing a camelid with a target antigen, isolating antigen-specific B cells and directly cloning dAb genes from individual B cells. dAbs are also producible in cell culture. Their small size, good solubility and temperature stability makes them particularly physiologically useful and suitable for selection and affinity maturation. A binding member of the present invention may be a dAb comprising a VH or VL domain substantially as set out herein, or a VH or VL domain comprising a set of CDRs substantially as set out herein.

35 [0060] As used herein, the phrase "substantially as set out" refers to the characteristic(s) of the relevant CDRs of the VH or VL domain of binding members described herein will be either identical or highly similar to the specified regions of which the sequence is set out herein. As described herein, the phrase "highly similar" with respect to specified region(s) of one or more variable domains, it is contemplated that from 1 to about 5, e.g. from 1 to 4, including 1 to 3, or 1 or 2, or 3 or 4, amino acid substitutions may be made in the CDR and/or VH or VL domain.

40 [0061] Bispecific or bifunctional antibodies form a second generation of monoclonal antibodies in which two different variable regions are combined in the same molecule (Holliger 1999). Their use has been demonstrated both in the diagnostic field and in the therapy field from their capacity to recruit new effector functions or to target several molecules on the surface of tumor cells. Where bispecific antibodies are to be used, these may be conventional bispecific antibodies, which can be manufactured in a variety of ways (Holliger 1993b), e.g. prepared chemically or from hybrid hybridomas, or may be any of the bispecific antibody fragments mentioned above. These antibodies can be obtained by chemical methods (Glennie 1987; Repp 1995) or somatic methods (Staerz 1986; Suresh 1986) but likewise by genetic engineering techniques which allow the heterodimerization to be forced and thus facilitate the process of purification of the antibody sought (Merchand 1998). Examples of bispecific antibodies include those of the BiTE™ technology in which the binding domains of two antibodies with different specificity can be used and directly linked via short flexible peptides. This

combines two antibodies on a short single polypeptide chain. Diabodies and scFv can be constructed without an Fc region, using only variable domains, potentially reducing the effects of anti-idiotypic reaction.

[0062] Bispecific antibodies can be constructed as entire IgG, as bispecific Fab'2, as Fab'PEG, as diabodies or else as bispecific scFv. Further, two bispecific antibodies can be linked using routine methods known in the art to form

tetravalent antibodies.

[0063] Bispecific diabodies, as opposed to bispecific whole antibodies, may also be particularly useful because they can be readily constructed and expressed in *E. coli*. Diabodies (and many other polypeptides such as antibody fragments) of appropriate binding specificities can be readily selected using phage display (WO94/13804) from libraries. If one arm of the diabody is to be kept constant, for instance, with a specificity directed against a target antigen, then a library can be made where the other arm is varied and an antibody of appropriate specificity selected. Bispecific whole antibodies may be made by alternative engineering methods as described in Ridgeway 1996.

[0064] Various methods are available in the art for obtaining antibodies against a target antigen. The antibodies may be monoclonal antibodies, especially of human, murine, chimeric or humanized origin, which can be obtained according to the standard methods well known to the person skilled in the art.

[0065] In general, for the preparation of monoclonal antibodies or their functional fragments, especially of murine origin, it is possible to refer to techniques which are described in particular in the manual "Antibodies" (Harlow and Lane 1988) or to the technique of preparation from hybridomas described by Kohler and Milstein, 1975.

[0066] Monoclonal antibodies can be obtained, for example, from an animal cell immunized against A-FN, or one of its fragments containing the epitope recognized by said monoclonal antibodies, e.g. a fragment comprising or consisting of ED-A, or a peptide fragment of ED-A. The A-FN, or one of its fragments, can especially be produced according to the usual working methods, by genetic recombination starting with a nucleic acid sequence contained in the cDNA sequence coding for A-FN or fragment thereof, by peptide synthesis starting from a sequence of amino acids comprised in the peptide sequence of the A-FN and/or fragment thereof.

[0067] Monoclonal antibodies can, for example, be purified on an affinity column on which A-FN or one of its fragments containing the epitope recognized by said monoclonal antibodies, e.g. a fragment comprising or consisting of ED-A or a peptide fragment of ED-A, has previously been immobilized. Monoclonal antibodies can be purified by chromatography on protein A and/or G, followed or not followed by ion-exchange chromatography aimed at eliminating the residual protein contaminants as well as the DNA and the LPS, in itself, followed or not followed by exclusion chromatography on Sepharose gel in order to eliminate the potential aggregates due to the presence of dimers or of other multimers. The whole of these techniques may be used simultaneously or successively.

Antigen-binding site

[0068] This describes the part of a molecule that binds to and is complementary to all or part of the target antigen. In an antibody molecule it is referred to as the antibody antigen-binding site, and comprises the part of the antibody that binds to and is complementary to all or part of the target antigen. Where an antigen is large, an antibody may only bind to a particular part of the antigen, which part is termed an epitope. An antibody antigen-binding site may be provided by one or more antibody variable domains. An antibody antigen-binding site may comprise an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

Isolated

[0069] This refers to the state in which binding members for use in the invention or nucleic acid encoding such binding members, will generally be in accordance with the present invention. Thus, binding members, VH and/or VL domains of the present disclosure may be provided isolated and/or purified, e.g. from their natural environment, in substantially pure or homogeneous form, or, in the case of nucleic acid, free or substantially free of nucleic acid or genes of origin other than the sequence encoding a polypeptide with the required function. Isolated members and isolated nucleic acid will be free or substantially free of material with which they are naturally associated such as other polypeptides or nucleic acids with which they are found in their natural environment, or the environment in which they are prepared (e.g. cell culture) when such preparation is by recombinant DNA technology practised *in vitro* or *in vivo*. Members and nucleic acid may be formulated with diluents or adjuvants and still for practical purposes be isolated - for example the members will normally be mixed with gelatin or other carriers if used to coat microtitre plates for use in immunoassays, or will be mixed with pharmaceutically acceptable carriers or diluents when used in diagnosis or therapy. Binding members may be glycosylated, either naturally or by systems of heterologous eukaryotic cells (e.g. CHO or NS0 (ECACC 85110503) cells, or they may be (for example if produced by expression in a prokaryotic cell) unglycosylated.

[0070] Heterogeneous preparations comprising antibody molecules may also be used in the invention. For example, such preparations may be mixtures of antibodies with full-length heavy chains and heavy chains lacking the C-terminal lysine, with various degrees of glycosylation and/or with derivatized amino acids, such as cyclization of an N-terminal

glutamic acid to form a pyroglutamic acid residue.

[0071] One or more binding members for an antigen, e.g. the A-FN or the ED-A of fibronectin, may be obtained by bringing into contact a library of binding members according to the invention and the antigen or a fragment thereof, e.g. a fragment comprising or consisting of ED-A or a peptide fragment of ED-A and selecting one or more binding members of the library able to bind the antigen.

[0072] An antibody library may be screened using Iterative Colony Filter Screening (ICFS). In ICFS, bacteria containing the DNA encoding several binding specificities are grown in a liquid medium and, once the stage of exponential growth has been reached, some billions of them are distributed onto a growth support consisting of a suitably pre-treated membrane filter which is incubated until completely confluent bacteriae colonies appear. A second trap substrate consists of another membrane filter, pre-humidified and covered with the desired antigen.

[0073] The trap membrane filter is then placed onto a plate containing a suitable culture medium and covered with the growth filter with the surface covered with bacterial colonies pointing upwards. The sandwich thus obtained is incubated at room temperature for about 16 h. It is thus possible to obtain the expression of the genes encoding antibody fragments scFv having a spreading action, so that those fragments binding specifically with the antigen which is present on the trap membrane are trapped. The trap membrane is then treated to point out bound antibody fragments scFv with colorimetric techniques commonly used to this purpose.

[0074] The position of the coloured spots on the trap filter allows to go back to the corresponding bacterial colonies which are present on the growth membrane and produced the antibody fragments trapped. Such colonies are gathered and grown and the bacteria-a few millions of them are distributed onto a new culture membrane repeating the procedures described above. Analogous cycles are then carried out until the positive signals on the trap membrane correspond to single positive colonies, each of which represents a potential source of monoclonal antibody fragments directed against the antigen used in the selection. ICFS is described in e.g. WO0246455.

A library may also be displayed on particles or molecular complexes, e.g. replicable genetic packages such bacteriophage (e.g. T7) particles, or other *in vitro* display systems, each particle or molecular complex containing nucleic acid encoding the antibody VH variable domain displayed on it, and optionally also a displayed VL domain if present. Phage display is described in WO92/01047 and e.g. US patents US5969108, US5565332, US5733743, US5858657, US5871907, US5872215, US5885793, US5962255, US6140471, US6172197, US6225447, US6291650, US6492160 and US6521404.

[0075] Following selection of binding members able to bind the antigen and displayed on bacteriophage or other library particles or molecular complexes, nucleic acid may be taken from a bacteriophage or other particle or molecular complex displaying a said selected binding member. Such nucleic acid may be used in subsequent production of a binding member or an antibody VH or VL variable domain by expression from nucleic acid with the sequence of nucleic acid taken from a bacteriophage or other particle or molecular complex displaying a said selected binding member.

[0076] An antibody VH variable domain with the amino acid sequence of an antibody VH variable domain of a said selected binding member may be provided in isolated form, as may a binding member comprising such a VH domain.

[0077] Ability to bind the A-FN or the ED-A of fibronectin or other target antigen or isoform may be further tested, e.g. ability to compete with e.g. any one of anti-ED-A antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9 for binding to the A-FN or a fragment of the A-FN, e.g. the ED-A of fibronectin.

[0078] A binding member for use in the disclosure may bind the A-FN and/or the ED-A of fibronectin specifically. A binding member of the present disclosure may bind the A-FN and/or the ED-A of fibronectin with the same affinity as anti-ED-A antibody H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9, e.g. in scFv format, or with an affinity that is better. A binding member for use in the invention may bind the A-FN and/or the ED-A of fibronectin with a K_D of 3×10^{-8} M or an affinity that is better. Preferably, a binding member for use in the invention binds the A-FN and/or the ED-A of fibronectin with a K_D of 2×10^{-8} M or an affinity that is better. More preferably, a binding member for use in the disclosure binds the A-FN and/or the ED-A of fibronectin with a K_D of 1.7×10^{-8} M or an affinity that is better. Yet more preferably, a binding member for use in the disclosure binds the A-FN and/or the ED-A of fibronectin with a K_D of 1.4×10^{-8} M or an affinity that is better. Most preferably, a binding member for use in the disclosure binds the A-FN and/or the ED-A of fibronectin with a K_D of 3×10^{-9} M or an affinity that is better.

[0079] A binding member of the present disclosure may bind to the same epitope on A-FN and/or the ED-A of fibronectin as anti-ED-A antibody H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9.

[0080] A binding member for use in the disclosure may not show any significant binding to molecules other than the A-FN and/or the ED-A of fibronectin. In particular the binding member may not bind other isoforms of fibronectin, for example the ED-B isoform and/or the IIIIS isoform of fibronectin.

[0081] Variants of antibody molecules disclosed herein may be produced and used in the present disclosure. The techniques required to make substitutions within amino acid sequences of CDRs, antibody VH or VL domains and binding members generally are available in the art. Variant sequences may be made, with substitutions that may or may not be predicted to have a minimal or beneficial effect on activity, and tested for ability to bind A-FN and/or the ED-A of fibronectin and/or for any other desired property.

[0082] Variable domain amino acid sequence variants of any of the VH and VL domains whose sequences are specifically disclosed herein may be employed in accordance with the present disclosure, as discussed. Particular variants may include one or more amino acid sequence alterations (addition, deletion, substitution and/or insertion of an amino acid residue), may be less than about 20 alterations, less than about 15 alterations, less than about 10 alterations or less than about 5 alterations, maybe 5, 4, 3, 2 or 1. Alterations may be made in one or more framework regions and/or one or more CDRs. The alterations normally do not result in loss of function, so a binding member comprising a thus-altered amino acid sequence may retain an ability to bind A-FN and/or the ED-A of fibronectin. For example, it may retain the same quantitative binding as a binding member in which the alteration is not made, e.g. as measured in an assay described herein. The binding member comprising a thus-altered amino acid sequence may have an improved ability to bind A-FN and/or the ED-A of fibronectin.

[0083] Novel VH or VL regions carrying CDR-derived sequences for use in the disclosure may be generated using random mutagenesis of one or more selected VH and/or VL genes to generate mutations within the entire variable domain. In some disclosures one or two amino acid substitutions are made within an entire variable domain or set of CDRs. Another method that may be used is to direct mutagenesis to CDR regions of VH or VL genes.

[0084] As noted above, a CDR amino acid sequence substantially as set out herein may be carried as a CDR in a human antibody variable domain or a substantial portion thereof. The HCDR3 sequences substantially as set out herein represent embodiments of the present invention and for example each of these may be carried as a HCDR3 in a human heavy chain variable domain or a substantial portion thereof.

[0085] Variable domains employed in the invention may be obtained or derived from any germ-line or rearranged human variable domain, or as disclosed may be a synthetic variable domain based on consensus or actual sequences of known human variable domains. A variable domain can be derived from a non-human antibody. A CDR sequence for use in the invention (e.g. CDR3) may be introduced into a repertoire of variable domains lacking a CDR (e.g. CDR3), using recombinant DNA technology. For example, Marks et al. (1992) describe methods of producing repertoires of antibody variable domains in which consensus primers directed at or adjacent to the 5' end of the variable domain area are used in conjunction with consensus primers to the third framework region of human VH genes to provide a repertoire of VH variable domains lacking a CDR3. Marks et al. further describe how this repertoire may be combined with a CDR3 of a particular antibody. Using analogous techniques, the CDR3-derived sequences of the present invention may be shuffled with repertoires of VH or VL domains lacking a CDR3, and the shuffled complete VH or VL domains combined with a cognate VL or VH domain to provide binding members for use in the invention. The repertoire may then be displayed in a suitable host system such as the phage display system of WO92/01047, or any of a subsequent large body of literature, including Kay, Winter & McCafferty (1996), so that suitable binding members may be selected. A repertoire may consist of from anything from 10^4 individual members upwards, for example at least 10^5 , at least 10^6 , at least 10^7 , at least 10^8 , at least 10^9 or at least 10^{10} members.

[0086] Similarly, one or more, or all three CDRs may be grafted into a repertoire of VH or VL domains that are then screened for a binding member or binding members for the A-FN and/or the ED-A of fibronectin.

[0087] One or more of the HCDR1, HCDR2 and HCDR3 of antibody H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9, or the set of HCDRs may be employed, and/or one or more of the X LCDR1, LCDR2 and LCDR3 of antibody H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9 or the set of LCDRs of antibody H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 or G9 may be employed.

[0088] Similarly, other VH and VL domains, sets of CDRs and sets of HCDRs and/or sets of LCDRs disclosed herein may be employed.

[0089] The A-FN and/or the ED-A of fibronectin may be used in a screen for binding members, e.g. antibody molecules, for use in the preparation of a medicament for the treatment of rheumatoid arthritis. The screen may be a screen of a repertoire as disclosed elsewhere herein.

[0090] A substantial portion of an immunoglobulin variable domain may comprise at least the three CDR regions, together with their intervening framework regions. The portion may also include at least about 50% of either or both of the first and fourth framework regions, the 50% being the C-terminal 50% of the first framework region and the N-terminal 50% of the fourth framework region. Additional residues at the N-terminal or C-terminal end of the substantial part of the variable domain may be those not normally associated with naturally occurring variable domain regions. For example, construction of binding members of the present invention made by recombinant DNA techniques may result in the introduction of N- or C-terminal residues encoded by linkers introduced to facilitate cloning or other manipulation steps. Other manipulation steps include the introduction of linkers to join variable domains disclosed elsewhere herein to further protein sequences including antibody constant regions, other variable domains (for example in the production of diabodies) or detectable/functional labels as discussed in more detail elsewhere herein.

[0091] Although binding members may comprise a pair of VH and VL domains, single binding domains based on either VH or VL domain sequences may also be used in the invention. It is known that single immunoglobulin domains, especially VH domains, are capable of binding target antigens in a specific manner. For example, see the discussion of dAbs above.

[0092] In the case of either of the single binding domains, these domains may be used to screen for complementary

domains capable of forming a two-domain binding member able to bind A-FN and/or the ED-A of fibronectin. This may be achieved by phage display screening methods using the so-called hierarchical dual combinatorial approach as disclosed in WO92/01047, in which an individual colony containing either an H or L chain clone is used to infect a complete library of clones encoding the other chain (L or H) and the resulting two-chain binding member is selected in accordance with phage display techniques such as those described in that reference. This technique is also disclosed in Marks 1992.

[0093] Binding members for use in the present invention may further comprise antibody constant regions or parts thereof, e.g. human antibody constant regions or parts thereof. For example, a VL domain may be attached at its C-terminal end to antibody light chain constant domains including human C κ or C λ , chains, e.g. C λ . Similarly, a binding member based on a VH domain may be attached at its C-terminal end to all or part (e.g. a CH1 domain) of an immunoglobulin heavy chain derived from any antibody isotype, e.g. IgG, IgA, IgE and IgM and any of the isotype sub-classes, particularly IgG1 and IgG4. Any synthetic or other constant region variant that has these properties and stabilizes variable regions is also useful in embodiments of the present invention.

[0094] Binding members for use in the disclosure may be labelled with a detectable or functional label. A label can be any molecule that produces or can be induced to produce a signal, including but not limited to fluorescers, radiolabels, enzymes, chemiluminescers or photosensitizers. Thus, binding may be detected and/or measured by detecting fluorescence or luminescence, radioactivity, enzyme activity or light absorbance. Detectable labels may be attached to antibodies for use in the invention using conventional chemistry known in the art.

[0095] There are numerous methods by which the label can produce a signal detectable by external means, for example, by visual examination, electromagnetic radiation, heat, and chemical reagents. The label can also be bound to another binding member that binds the antibody for use in the disclosure, or to a support.

[0096] Labelled binding members, e.g. scFv labelled with a detectable label, may be used diagnostically *in vivo*, *ex vivo* or *in vitro*, and/or therapeutically.

[0097] For example, radiolabelled binding members (e.g. binding members conjugated to a radioisotope) may be used in radiodiagnosis and radiotherapy. Radioisotopes which may be conjugated to a binding member for use in the invention include isotopes such as ^{94m}Tc, ^{99m}Tc, ¹⁸⁶Re, ¹⁸⁸Re, ²⁰³Pb, ⁶⁷Ga, ⁶⁸Ga, ⁴⁷Sc, ¹¹¹In, ⁹⁷Ru, ⁶²Cu, ⁶⁴Cu, ⁸⁶Y, ⁸⁸Y, ⁹⁰Y, ¹²¹Sn, ¹⁶¹Tb, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁰⁵Rh, ¹⁷⁷Lu, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I.

[0098] For example, a binding member for use in the disclosure labelled with a detectable label may be used to detect, diagnose or monitor rheumatoid arthritis in a human or animal.

[0099] A binding member of the present disclosure may be used for the manufacture of a diagnostic product for use in diagnosing rheumatoid arthritis.

[0100] The present disclosure provides a method of detecting or diagnosing rheumatoid arthritis in a human or animal comprising:

- (a) administering to the human or animal a binding member of the present invention, for example labelled with a detectable label, which binds the ED-A isoform of fibronectin and/or the ED-A of fibronectin, and
- (b) determining the presence or absence of the binding member in neovasculature of the human or animal body;

wherein localisation of the binding member to neovasculature in the human or animal is indicative of the presence of rheumatoid arthritis.

[0101] Where the binding member is labelled with a detectable label, the presence or absence of the detectable label may be determined by detecting the label.

[0102] A conjugate or fusion between a binding member for use in the invention and a molecule that exerts a biocidal, cytotoxic immunosuppressive or anti-inflammatory effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions may be employed in the present invention. For example, the conjugated molecule may be *inter alia* interleukin-10, an anti-inflammatory or other drug, a photosensitizer or a radionuclide. Such conjugates may be used therapeutically, e.g. for treatment of rheumatoid arthritis as referred to herein.

[0103] Production and use of fusions or conjugates of binding members with biocidal or cytotoxic molecules is described for example in WO01/62298.

[0104] The invention provides a method of treating rheumatoid arthritis, the method comprising administering to an individual a therapeutically effective amount of a medicament comprising a binding member for use in the invention.

[0105] The binding member may be a conjugate of (i) a molecule which exerts an anti-inflammatory effect on target cells by cellular interaction, an anti-inflammatory molecule, IL-10, TGF beta, or other drug, and (ii) a binding member for the ED-A isoform of fibronectin and/or the ED-A of fibronectin.

[0106] The binding member may be a conjugate of (i) a molecule which exerts an immunosuppressive or anti-inflammatory effect and (ii) a binding member for the ED-A isoform of fibronectin and/or the ED-A of fibronectin.

[0107] The binding member may be a conjugate of (i) interleukin-10 (IL10) or TGF beta and (ii) a binding member for the ED-A isoform of fibronectin and/or the ED-A of fibronectin. Such a binding member is useful in aspects of the invention

disclosed herein relating to treatment of rheumatoid arthritis.

[0108] The disclosure provides the use of a binding member for use in the invention for the preparation of a medicament for the treatment of rheumatoid arthritis.

[0109] The binding member may be a conjugated or fused to a molecule that exerts a biocidal, cytotoxic, immunosuppressive or anti-inflammatory effect as described herein. The binding member may be a conjugate of (i) a molecule which exerts a biocidal or cytotoxic effect on target cells by cellular interaction or has an immunosuppressive or anti-inflammatory effect and (ii) a binding member for human fibronectin according to the present invention.

[0110] Also described herein is a conjugate of (i) a molecule which exerts a biocidal or cytotoxic effect on target cells by cellular interaction, or an immunosuppressive or anti-inflammatory effect and (ii) a binding member for human fibronectin according for use in the present invention. Such a conjugate preferably comprises a fusion protein comprising the biocidal, cytotoxic, immunosuppressive or anti-inflammatory molecule and a said binding member, or, where the binding member is two-chain or multi-chain, a fusion protein comprising the biocidal, cytotoxic, immunosuppressive or anti-inflammatory molecule and a polypeptide chain component of said binding member. Preferably the binding member is a single-chain polypeptide, e.g. a single-chain antibody molecule, such as scFv.

[0111] A fusion protein comprising the immunosuppressive or anti-inflammatory molecule and a single-chain Fv antibody molecule may be used in the invention.

[0112] The immunosuppressive or anti-inflammatory molecule that exerts its effect on target cells by cellular interaction, may interact directly with the target cells, may interact with a membrane-bound receptor on the target cell or perturb the electrochemical potential of the cell membrane. In an exemplary preferred embodiment the molecule is IL-10.

[0113] As discussed further below, the specific binding member is preferably an antibody or comprises an antibody antigen-binding site. Conveniently, the specific binding member may be a single-chain polypeptide, such as a single-chain antibody. This allows for convenient production of a fusion protein comprising single-chain antibody and immunosuppressive or anti-inflammatory molecule (e.g. interleukin-10 or TGF beta. An antibody antigen-binding site may be provided by means of association of an antibody VH domain and an antibody VL domain in separate polypeptides, e.g. in a complete antibody or in an antibody fragment such as Fab or diabody. Where the specific binding member is a two-chain or multi-chain molecule (e.g. Fab or whole antibody, respectively), the immunosuppressive or anti-inflammatory molecule may be conjugated as a fusion polypeptide with one or more polypeptide chains in the specific binding member.

[0114] The binding member may be conjugated with the immunosuppressive or anti-inflammatory molecule by means of a peptide bond, i.e. within a fusion polypeptide comprising said molecule and the specific binding member or a polypeptide chain component thereof (see e.g. Trachsel et al.). Other means for conjugation include chemical conjugation, especially cross-linking using a bifunctional reagent (e.g. employing DOUBLE-REAGENTS™ Cross-linking Reagents Selection Guide, Pierce).

[0115] Also described herein is isolated nucleic acid encoding a binding member for use in the present invention. Nucleic acid may include DNA and/or RNA. A nucleic acid may code for a CDR or set of CDRs or VH domain or VL domain or antibody antigen-binding site or antibody molecule, e.g. scFv or IgG, e.g. IgG1, as defined above. The nucleotide sequences may encode the VH and/or VL domains disclosed herein.

[0116] Further described herein are constructs in the form of plasmids, vectors, transcription or expression cassettes which comprise at least one polynucleotide as described above.

[0117] A recombinant host cell that comprises one or more constructs as above are also described. A nucleic acid encoding any CDR or set of CDRs or VH domain or VL domain or antibody antigen-binding site or antibody molecule, e.g. scFv or IgG1 or IgG4 as provided, is described, as is a method of production of the encoded product, which method comprises expression from encoding nucleic acid. Expression may conveniently be achieved by culturing under appropriate conditions recombinant host cells containing the nucleic acid. Following production by expression a VH or VL domain, or binding member may be isolated and/or purified using any suitable technique, then used as appropriate.

[0118] A nucleic acid may comprise DNA or RNA and may be wholly or partially synthetic. Reference to a nucleotide sequence as set out herein encompasses a DNA molecule with the specified sequence, and encompasses a RNA molecule with the specified sequence in which U is substituted for T, unless context requires otherwise.

[0119] A method of production of an antibody VH variable domain, the method including causing expression from encoding nucleic acid is also described. Such a method may comprise culturing host cells under conditions for production of said antibody VH variable domain.

[0120] A method of production may comprise a step of isolation and/or purification of the product. A method of production may comprise formulating the product into a composition including at least one additional component, such as a pharmaceutically acceptable excipient.

[0121] Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, mammalian cells, plant cells, filamentous fungi, yeast and baculovirus systems and transgenic plants and animals. The expression of antibodies and antibody fragments in prokaryotic cells is well established in the art. For a review, see for example Pluckthun 1991. A common bacterial host is *E. coli*.

[0122] Expression in eukaryotic cells in culture is also available to those skilled in the art as an option for production

of a binding member for example Chadd & Chamow (2001), Andersen & Krummen (2002), Larrick & Thomas (2001). Mammalian cell lines available in the art for expression of a heterologous polypeptide include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney cells, NS0 mouse melanoma cells, YB2/0 rat myeloma cells, human embryonic kidney cells, human embryonic retina cells and many others.

5 [0123] Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids e.g. phagemid, or viral e.g. phage, as appropriate. For further details see, for example, Sambrook & Russell (2001). Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene

10 expression, and analysis of proteins, are described in detail in Ausubel 1999. [0124] A host cell may contain a nucleic acid as described herein. Such a host cell may be *in vitro* and may be in culture. Such a host cell may be *in vivo*. *In vivo* presence of the host cell may allow intracellular expression of a binding member for use in the present invention as "intrabodies" or intracellular antibodies. Intrabodies may be used for gene therapy.

15 [0125] A method comprising introducing a nucleic acid disclosed herein into a host cell is also described. The introduction may employ any available technique. For eukaryotic cells, suitable techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, liposome-mediated transfection and transduction using retrovirus or other virus, e.g. vaccinia or, for insect cells, baculovirus. Introducing nucleic acid in the host cell, in particular a eukaryotic cell may use a viral or a plasmid based system. The plasmid system may be maintained episomally or may be incorporated

20 into the host cell or into an artificial chromosome. Incorporation may be either by random or targeted integration of one or more copies at single or multiple loci. For bacterial cells, suitable techniques may include calcium chloride transformation, electroporation and transfection using bacteriophage. [0126] The introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells under conditions for expression of the gene. The purification of the expressed product may be achieved by

25 methods known to one of skill in the art. [0127] The nucleic acid may be integrated into the genome (e.g. chromosome) of the host cell. Integration may be promoted by inclusion of sequences that promote recombination with the genome, in accordance with standard techniques.

30 [0128] A method that comprises using a construct as stated above in an expression system in order to express a binding member or polypeptide as above is also described.

[0129] Binding members for use in the present disclosure are designed to be used in methods of diagnosis or treatment in human or animal subjects, e.g. human. Binding members for use in the disclosure may be used in diagnosis or treatment of rheumatoid arthritis.

35 [0130] Accordingly, the disclosure provides methods of treatment comprising administration of a binding member as provided, pharmaceutical compositions comprising such a binding member, and use of such a binding member in the manufacture of a medicament for administration, for example in a method of making a medicament or pharmaceutical composition comprising formulating the binding member with a pharmaceutically acceptable excipient. Pharmaceutically acceptable vehicles are well known and will be adapted by the person skilled in the art as a function of the nature and of the mode of administration of the active compound(s) chosen.

40 [0131] Binding members for use in the present disclosure will usually be administered in the form of a pharmaceutical composition, which may comprise at least one component in addition to the binding member. Thus pharmaceutical compositions according to the present invention, and for use in accordance with the present disclosure, may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, inhaled or by injection, e.g. intravenous.

45 [0132] Pharmaceutical compositions for oral administration such as for example nanobodies etc are also envisaged in the present invention. Such oral formulations may be in tablet, capsule, powder, liquid or semi-solid form. A tablet may comprise a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

50 [0133] For intravenous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilizers, buffers, antioxidants and/or other additives may be employed, as required. Many methods for the preparation of pharmaceutical formulations are known to those skilled in the art. See e.g. Robinson, 1978.

[0134] A composition may be administered alone or in combination with other treatments, concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, dependent upon the condition to be treated.

[0135] A binding member for use in the present disclosure may be used as part of a combination therapy in conjunction with an additional medicinal component. Combination treatments may be used to provide significant synergistic effects, particularly the combination of a binding member for use in the present disclosure with one or more other drugs. A binding member for use in the present invention may be administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed herein.

[0136] For example, a binding member for use in the disclosure may be used in combination with an existing therapeutic agent for the treatment of rheumatoid arthritis.

[0137] Existing therapeutic agents for the treatment of rheumatoid arthritis include IL-10, TGFbeta, photosensitizers and cytotoxic drugs.

[0138] A binding member for use in the disclosure and one or more of the above additional medicinal components may be used in the manufacture of a medicament. The medicament may be for separate or combined administration to an individual, and accordingly may comprise the binding member and the additional component as a combined preparation or as separate preparations. Separate preparations may be used to facilitate separate and sequential or simultaneous administration, and allow administration of the components by different routes e.g. oral and parenteral administration.

[0139] In accordance with the present disclosure, compositions provided may be administered to mammals. Administration may be in a "therapeutically effective amount", this being sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. Thus "treatment of rheumatoid arthritis" refers to amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the composition, the type of binding member, the method of administration, the scheduling of administration and other factors known to medical practitioners. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and may depend on the severity of the symptoms and/or progression of a disease being treated. Appropriate doses of antibody are well known in the art (Ledermann 1991 and Bagshawe 1991. Specific dosages indicated herein, or in the Physician's Desk Reference (2003) as appropriate for the type of medicament being administered, may be used. A therapeutically effective amount or suitable dose of a binding member for use in the invention can be determined by comparing its *in vitro* activity and *in vivo* activity in an animal model. Methods for extrapolation of effective dosages in mice and other test animals to humans are known. The precise dose will depend upon a number of factors, including whether the antibody is for diagnosis, prevention or for treatment, the size and location of the area to be treated, the precise nature of the antibody (e.g. whole antibody, fragment or diabody), and the nature of any detectable label or other molecule attached to the antibody. A typical antibody dose will be in the range 100 µg to 1 g for systemic applications, and 1 µg to 1 mg for topical applications. An initial higher loading dose, followed by one or more lower doses, may be administered. An antibody may be a whole antibody, e.g. the IgG1 or IgG4 isotype. This is a dose for a single treatment of an adult patient, which may be proportionally adjusted for children and infants, and also adjusted for other antibody formats in proportion to molecular weight. Treatments may be repeated at daily, twice-weekly, weekly or monthly intervals, at the discretion of the physician. Treatments may be every two to four weeks for subcutaneous administration and every four to eight weeks for intravenous administration. In some embodiments of the present disclosure, treatment is periodic, and the period between administrations is about two weeks or more, e.g. about three weeks or more, about four weeks or more, or about once a month. In other embodiments of the disclosure, treatment may be given before, and/or after surgery, and may be administered or applied directly at the anatomical site of surgical treatment.

[0140] Further aspects and embodiments of the disclosure will be apparent to those skilled in the art given the present disclosure including the following experimental exemplification.

EXPERIMENTAL

RESULTS

Histochemical analysis of human arthritic specimens

[0141] Expression of fibronectin domains EDA and EDB as well as tenascin-C domains A1 and C were investigated by immunohistochemistry on human arthritic specimens using the F8, L19, F16 and G11 antibodies respectively.

[0142] In Figure 1 darker staining indicates expression of the respective antigens (indicated with white arrows). The anti-EDA antibody F8 led to the strongest staining, therefore all further experiments were performed with this antibody.

[0143] Immunofluorescence experiments with the F8 antibody were performed which showed a nice perivascular staining (visible as white structures in Figure 2).

The human monoclonal antibody F8 selectively accumulates at sites of arthritis in mice

[0144] We studied the in vivo targeting performance of F8 in mini-antibody format (SIP) (Borsi et al. 2002) in the CIA mouse model (Courtney et al. 1980) using both fluorescence and radioactivity for antibody detection. The SIP format consists of a scFv antibody fragment linked to the CH4 domain of human IgE giving rise to a homodimeric protein of 80kDa in size.

[0145] Arthritic mice were injected with SIP(F8) labelled with the near-infrared dye Alexa 750. Twenty-four hours after intravenous injection, animals were imaged using an infrared fluorescence imager (Birchler et al., 1999), revealing a strong and selective antibody accumulation in the lesions present in the arthritic limb, visible as white lighting paws, with some grade 2 swelling in front paws of the mice.

[0146] Twenty-four hours after intravenous injection of SIP(F8) radioactively labelled with ¹²⁵I, mice were sacrificed and paws imaged by autoradiography (phosphorimaging). A preferential accumulation of radioactivity was observed in the inflamed extremities of mice injected with SIP(F8), visible as black staining in autoradiography. One paw showed an arthritic score of 2 (swelling of the whole paw). Another paw was classified as grade 1 arthritis (swelling of single fingers).

Activity of anti-ED-A antibody-interleukin-10 fusion

[0147] Antibody molecule F8 in scFv format was conjugated within a fusion protein with interleukin-10 (IL-10). Biological activity of the fusion protein was compared with that of human IL-10 in an assay determining ability to induce IL-4 dependent proliferation of MC/9 cells (Thompson et al., 1991). The results are shown in Figure 8(d).

MATERIALS AND METHODS*Immunohistochemical analysis on human arthritic specimens*

[0148] Frozen sections of human arthritic specimens were fixed in ice-cold acetone for 10', blocked with Fetal Bovine Serum for 30' and stained for markers of neovasculature (Fibronectin ED-A and ED-B, Tenascin-C domain A1 and C). The F8, L19, F16 and G11 antibodies were used as myc-tagged scFvs in a concentration of 10 ug/ml and incubated for 1 h. The primary antibodies were coincubated with the anti-myc antibody 9E10 in concentration of 7ug/ml. As tertiary detection antibody a rabbit anti-mouse IgG antibody (Dako, Denmark) and APAAP Mouse Monoclonal (Dako, Denmark) were used in concentrations of 5 and 50 ug/ml respectively for 1 h each. Fast Red Tablets (Sigma, Switzerland) were used to develop the staining incubating for 15'. Slides were counterstained with hematoxylin for 2', washed with water, mounted with Glycergel mounting medium (Dako, Denmark) and analyzed with a Axiovert S100 TV microscope (Zeiss, Switzerland).

Immunofluorescence analysis on human arthritic specimens

[0149] Frozen sections of human arthritic specimens were fixed in ice-cold acetone for 10', blocked with Fetal Bovine Serum for 30' and stained for the EDA domain of fibronectin. The F8 antibody was used as a myc-tagged scFv in a concentration of 10 ug/ml and incubated for 1 h. The primary antibody was coincubated with the anti-myc antibody 9E10 in a concentration of 7ug/ml. As tertiary detection antibody a fluorescent anti-mouse-Alexa 596 antibody (Molecular Probes, Denmark) was used in a concentration of 10 ug/ml for 1 h each. Slides were counterstained with Hoechst 33342, mounted with Glycergel mounting medium (Dako, Denmark) and analyzed with a AxioScop 2MOT+ microscope (Zeiss, Switzerland).

Animal model

[0150] Male DBA/1 mice (8-12 weeks old) were immunized by intradermal injection at the base of the tail of 200 µg of bovine type II collagen (MD Biosciences) emulsified with equal volumes of Freund's complete adjuvant (MD Biosciences). 2 weeks after the first immunization the procedure was repeated but incomplete Freund's adjuvant (MD Biosciences) was used to emulsify the collagen. Mice were inspected daily and each mouse that exhibited erythema and/or paw swelling in 1 or more limbs was assigned for imaging or treatment studies.

[0151] Arthritis was monitored using 2 disease indices (clinical score and paw swelling). For the clinical score each limb was graded daily in a not blinded fashion. (0 = normal, 1 = swelling of 1 or more fingers of the same limb, 2 = swelling of the whole paw), resulting in a maximum possible score of 8 per animal. Paw swelling was assessed every second day using a calliper to measure the thickness of each limb under isoflurane anaesthesia. The mean value of all 4 paws was assigned as paw thickness to each animal.

Near-Infrared-Imaging of arthritic paws

[0152] The selective accumulation of SIP(F8) in arthritic mice was tested by Near-Infrared-Imaging analysis as described by Birchler et al. (1999). Briefly, purified SIP(F8) was labelled with Alexa750 (MolecularProbes, Leiden, The Netherlands) according to the manufacturer's recommendations and 100ug of labelled protein were injected into the tail vein of arthritic mice. Mice were anesthetized with Ketamin 80 mg/kg and Medetomidin 0.2 mg/kg and imaged in a near-infrared-mouseimager 24 hr after injection (Trachsel et al. 2007; Birchler et al. 1999).

Biodistribution experiments

[0153] The *in vivo* targeting performance of SIP(F8) in arthritic mice was evaluated by biodistribution analysis as described before (Borsi et al. 2002; Tarli et al., 1999). Briefly, purified SIP(F8) was radioiodinated and 10 ug of protein, corresponding to 11uCi ¹²⁵I, were injected into the tail vein of arthritic mice. Mice were sacrificed 24 hr after injection and paws were exposed for 1 hour and read in a phosphorimager (Fujifilm BAS-5000) as described before (Trachsel et al. 2007).

Antibodies

[0154] The isolation of the anti-ED-B antibody fragment scFv(L19) has been previously described (Pini et al. 1998). The parent anti-ED-A antibody was isolated from the ETH-2 library using published procedures (Giovannoni, Nucleic Acid Research, 2001, 29(5):E27). The affinity maturation of the parent anti-ED-A antibody, yielding the high affinity anti-ED-A antibodies, is described in the following section.

Affinity maturation of the parent anti-ED-A antibody

[0155] The parent anti-ED-A antibody (an ETH-2-derived antibody) was used as template for the construction of an affinity maturation library. Sequence variability in the VH CDR1 (DP47 germline) and VL CDR1 (DPK22 germline) of the library was introduced by PCR using partially degenerate primers 5'-CTGGAGCCTGGCGGACCCAGCTCATMNMN-NMNGCTAAAGGTGAAT CCAGA-3' (SEQ ID NO: 17) for VH and 5'-CCAGGTTTCTGCTGGTACCAGGCTAA MN-NMNMNNGCTAACACTCTGACTGGCCCTGC-3' (SEQ ID NO: 18) for VL (all oligonucleotides were purchased from Operon Biotechnologies, Cologne, Germany), in a process that generates random mutations at positions 31, 32 and 33 of the VH CDR1 and at positions 31, 31a and 32 of the VL CDR1. VHVL combinations were assembled in scFv format by PCR assembly using the primers LMB3long (5'-CAGGAAACAGCTATGACCATGATTAC-3') (SEQ ID NO: 19) and fdseqlong (5'-GACGTTAGTAAATGAATTTTCTGTATGAGG-3') (SEQ ID NO: 20), using gel-purified VH and VL segments as templates. The assembled VH-VL fragments were doubly digested with NcoI/NotI and cloned into NcoI/NotI-digested pHEN1 phagemid vector (Hoogenboom et al., 1991). The resulting ligation product was electroporated into electrocompetent *E. coli* TG-1 cells according to (Viti et al., 2000), giving rise to a library containing 1.5 x 10⁷ individual antibody clones, which was screened for antibodies which bind ED-A with improved affinity.

Selection of anti-ED-A antibodies

[0156] The antibody library described above was screened for antibodies which bound ED-A with a greater affinity than the parent anti-ED-A antibody using BIAcore analysis. The antigen (11A12) used in the BIAcore analysis contained the ED-A domain of human fibronectin and has the following amino acid sequence (SEQ ID NO: 120) :

```
MRSYRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKTKTAGPDQ
TEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTNIDRPKGLAFTDVDVDSIKIAWES
PQGQVSRYRVTYSSPEDGIHELFPAPDGEEDTAE LQGLRPGSEYTVSVVALHDDMESQPL
IGTQSTAI PAPTDLKFTQVTP TSLSAQWTPPNVQLTGYRVRVTPKEKTGPMKEINLAPDS
SSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVRSHHHHHH
```

[0157] The nucleotide sequence of antigen (11A12) (SEQ ID NO: 121) is as follows:

EP 3 281 952 B1

atgagatcctaccgaacagaaattgacaaaccatcccagatgcaagtgaccgatgttcaggacaa
cagcattagtgtcaagtggctgccttcaagttcccctgttactggttacagagtaaccaccactc
5 ccaaaaatggaccaggaccaacaaaaactaaaactgcaggtccagatcaaacagaaatgactatt
gaaggcttgcagcccacagtgaggatgtgtggttagtgtctatgctcagaatccaagcggagagag
tcagcctctggttcagactgcagtaaccaacattgatgcacctaaaggactggcattcactgatg
10 tggatgtcgattccatcaaaattgcttgggaaagcccacaggggcaagtttccaggtacagggtg
acctactcgagccctgaggatggaatccatgagctattccctgcacctgatggtgagaagacac
tgcagagctgcaaggcctcagaccgggttctgagtacacagtcagtggttgccttgcacgatg
atatggagagccagcccctgattggaaccagtcacacagctattcctgcaccaactgacctgaag
15 ttactcaggtcacaccacaagcctgagcgcccagtggaacaccaccaatgttcagctcactgg
atatcgagtgcgggtgaccccccaaggagaagaccggaccaatgaaagaaatcaaccttgcctctg
20 acagctcatccgtggttgtatcaggacttatggtggccaccaaataatgaagtgagtgtctatgct
cttaaggacactttgacaagcagaccagctcagggagttgtcaccactctggagaatgtcagatc
tcataccatcaccatcactaa

25 **[0158]** The nucleotide sequence of the antigen was amplified by PCR using primers containing BamHI and BglII restriction sites at the 5' and 3' respectively. The resulting PCR product and the vector pQE12 (QIAGEN) were digested with BamHI and BglII restriction endonuclease and subsequently ligated in a reaction containing a ratio of insert to vector of 3:1. The resulting vector was sequenced to check that the sequence was correct.

Antigen preparation

30 **[0159]** A TG1 electrocompetent Preculture in 10 ml 2TY, Amp, 1% Glucose was electroporated in the presence of 1 μ l of a DNA miniprep of 11A12. The pre-culture was then diluted 1:100 (8ml in 800ml of 2TY, Amp, 0.1% Glucose) and grown to an OD600 of 0.4-0.6 and then induced with IPTG over night. The following day the cells were spun down and the supernatant filtered (Millipore 0.22 μ m).

35 After centrifugation and clarification of the culture broth, 11A12 was purified using a Hitrap column on FPLC. The Ni/ column was regenerated as follows: the column was rinsed with 5 column volumes (CV) H₂O followed by application of 3CV 0.5 M EDTA/0.2 M Tris pH 8 to wash the old Nickel out from the column. This was followed by rinsing of the column with 5CV H₂O. The column was then reloaded with 2CV 100 mM NiSO₄ followed by rinsing of the column with several CVs H₂O. The column was then equilibrated with 5CV lysis buffer (20 mM imidazol /250 mM NaCl/ PBS pH 7.4). The cell lysate was filtered (Millipore 0.45 μ m) and loaded onto the column (manually). The column was then put
40 back on FPLC and the lysis buffer left to flow until the UV signal was stable (constant), about 3 CV. The elution program was then started: Gradient from 0% to 100% of Elution Buffer (400 mM imidazol/250 mM NaCl/ PBS pH 7.4) in 5CV. The fractions containing the eluted antigen were pooled and dialysed in PBS over night.

Expression and Purification of the anti-ED-A antibodies

45 **[0160]** The anti-ED-A antibodies were expressed and purified as follows: A TG1 electrocompetent Preculture in 10 ml 2TY, Amp, 1% Glucose was electroporated in the presence of 1 μ l of a DNA miniprep of one of the anti-ED-A antibodies. The pre-culture was then diluted 1:100 (8ml in 800ml of 2TY, Amp, 0.1% Glucose) and grown to an OD600 of 0.4-0.6
50 and then induced with IPTG over night. The following day the cells were spun down and the supernatant filtered (Millipore 0,22 μ m). The scFv were purified on a Protein A-Sepharose column and Triethylemmine was used to elute the scFvs from the column. The fractions containing the eluted scFvs were dialysed in PBS over night at 4°C. The scFv fractions were then put on a Superdex 75 column with PBS flowing at 0.5 ml/min and 0.25 ml fractions collected. The monomeric fractions were used for BIAcore analysis.

BIAcore™ analysis 1

55 **[0161]** The BIAcore™ Chip was flushed overnight at a flow rate of 5 μ l/min with HBS-EP buffer BIAcore™, 0.01 M

EP 3 281 952 B1

Hepes pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20 (same buffer used for the assay). The antigen (11A12) was diluted to a concentration of 50 pg/ml in acetate buffer (pH 4.0) and the COOH groups on the chip were activated by injection of 50 μ l of a mix of N-Hydroxy Succinimide (NHS) and ethyl-N-(dimethylaminopropyl)-carbodiimide (EDC). 40 μ l of the 11A12 antigen were injected onto the chip and the residual free COOH groups were blocked with 30 μ l of ethanolamine. After a 0,22 μ m filtration, 20 μ l of each individual bacterial supernatant were injected onto the chip and interaction with the antigen was monitored in real time.

BIACore™ analysis 2

[0162] The k_{on} , k_{off} and K_D of the parent anti-ED-A antibody and anti-ED-A antibodies B2, C5, D5, C8, F8, B7 and G9 were evaluated using Surface Plasmon Resonance. The chip was equilibrated over night with the same buffer used during the assay at a buffer flow rate of 5 μ l/min. The whole coating procedure was performed at this flow rate. The antigen 11A12 was diluted 1:25 with acetate buffer pH 4.00 (provided by BIACORE™) to a final concentration of 20 pg/ml. The NHS and EDC were then mixed and 50 μ l injected to activate the COOH groups on the CM5 chip. This was followed by injection of 40 μ l of the antigen (this lasts about 40"). Then 30 μ l of Ethanolamine were injected in order to block the reactivity of eventual free COOH.

[0163] Each sample was assayed at a flow rate 20 μ l/min. 20 μ l of undiluted monomeric protein (as it comes out from the gel filtration) was injected. The dissociation time was left to run for about 200". Then 10 μ l of HCl 10mM was injected to regenerate the chip. The injection of monomeric protein was repeated at different dilutions, i.e. 1:2 dilution (in PBS) followed by regeneration with HCl. This was followed by a third injection of the protein, at a dilution of 1:4 followed again by regeneration with HCl. The k_{on} , k_{off} and K_D values for each anti-ED-A antibody were evaluated using the BIAevaluation software.

Selection of anti-ED-A antibodies

BIACore™ analysis 1

[0164] The BIACore™ analysis produced a graph for each anti-ED-A antibody which was analysed to deduce the affinity of an antibody for the antigen as follows: The x axis of each graph corresponds to time and the y axis corresponds to Resonance Units (a measure which indicates the binding affinity of the tested antibody for the antigen coated onto the BIACore™ chip). Each graph showed 3 peaks and 1 dip which correspond to changes of buffer and are therefore irrelevant for the interpretation of the results.

[0165] The ascending part of each graph represents the association phase. The steeper is the curve in this part of the graph, the faster is the association of the antibody with the antigen. The descending part of each graph represents the dissociation phase of the antibody from the antigen. The flatter the curve in this part of the graph is, the slower is the dissociation of the antibody from the antigen.

[0166] Anti-ED-A antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 and G9 all showed a flatter dissociation curve than the parent anti-ED-A antibody from which they were derived, indicating that they bind ED-A, and hence also A-FN, with a greater affinity than the parent anti-ED-A antibody. The graphs for antibodies E5, F1, F8 and H1 showed the flattest dissociation curves of all the anti-ED-A antibodies tested. The association curves of antibodies H1, C5, D5, E5, C8, F8 and F1 were flatter than that observed for the parent anti-ED-A antibody while the association curve observed for antibodies B2, B7, E8 and G9 was as steep as the association curve observed for the parent anti-ED-A antibody. However, as bacterial supernatants of IPTG-induced *E. coli* TG-1 cells were used for the BIACore™ analysis of antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 and G9, the concentration of the tested antibody samples was unknown but most probably lower than the concentration of the parent anti-ED-A antibody sample used for comparison. Consequently, the association curve of antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 and G9 may be artificially low due to the low concentration of antibody in the samples used for the BIACore™ analysis. However, as concentration does not significantly affect the dissociation of an antibody from its target antigen in BIACore™ analysis, the flat dissociation curves observed for antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 and G9 show that these antibodies bind ED-A with at least an equal, and probably a higher affinity, than the parent anti-ED-A antibody.

BIACore analysis 2

[0167] The k_{on} , k_{off} and K_D values for each anti-ED-A antibody were evaluated using the BIAevaluation software. The k_{on} , k_{off} and K_D values of the parent anti-ED-A antibody and anti-ED-A antibodies B2, C5, D5, C8, F8, B7 and G9 for antigen 11A12 are detailed in Table 2. Anti-ED-A antibodies B2, C5, D5, C8, F8, B7 and G9 all have a better K_D values for antigen 11A12 than the parent anti-ED-A antibody from which they were derived, indicating that they bind ED-A, and hence also A-FN, with a greater affinity than the parent anti-ED-A antibody.

Sequences

- 5 **[0168]** Anti-ED-A antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8 and G9 are all scFv antibodies and were sequenced using conventional methods. The nucleotide sequence of the anti-ED-A antibody H1 is shown in Figure 3. The amino acid sequence of the anti-ED-A antibody H1 is shown in Figure 4.
- [0169]** Preferred nucleotide sequences encoding VH and/or VL of anti-ED-A antibodies B2, C5, D5, E5, C8, F8, F1, B7, E8 and G9 are identical to nucleotide sequences encoding VH and/or VL of anti-ED-A antibody H1, except that the nucleotide sequences encoding the H1 CDR1s of the light (VL) and heavy (VH) chain are substituted with the nucleotide sequences encoding the light (VL) and heavy (VH) chain CDR1s listed in Table 1 for the respective antibody.
- 10 **[0170]** The preferred nucleotide sequences encoding the VH and/or VL of anti-ED-A scFv F8 diabody are identical to the nucleotide sequences encoding VH and/or VL of anti-ED-A antibody H1, except that the nucleotide sequences encoding the H1 CDR1s of the light (VL) and heavy (VH) chain are substituted with the nucleotide sequences encoding the light (VL) and heavy (VH) chain CDR1s listed in Table 1 for anti-ED-A antibody F8. The preferred nucleotide sequence encoding the linker linking the VH and VL of the anti-ED-A scFv F8 diabody is ggggccagtgccggg (SEQ ID NO: 29).
- 15 **[0171]** Anti-ED-A antibodies B2, C5, D5, E5, C8, F8, F1, B7, E8 and G9 have identical amino acid sequences to anti-ED-A antibody H1, except that the amino acid sequences of the H1 CDR1s of the light (VL) and heavy (VH) chain are substituted with the amino acid sequences of the light (VL) and heavy (VH) chain CDR1s listed in Table 1 for the respective antibody. The amino acid sequence of the anti-ED-A scFv F8 diabody is identical to the amino acid sequences of anti-ED-A antibody H1, except that the amino acid sequences of the H1 CDR1s of the light (VL) and heavy (VH) chain are substituted with the amino acid sequences of the light (VL) and heavy (VH) chain CDR1s listed in Table 1 for anti-ED-A antibody F8, and the amino acid sequence of the linker in H1 is substituted with the linker amino acid sequence GSSGG (SEQ ID NO: 28).
- [0172]** The amino acid sequence of the anti-ED-A antibody B2 VH domain (SEQ ID NO: 21) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 23 is substituted for the VH CDR1 of H1.
- 25 **[0173]** The amino acid sequence of the anti-ED-A antibody C5 VH domain (SEQ ID NO: 41) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 43 is substituted for the VH CDR1 of H1.
- [0174]** The amino acid sequence of the anti-ED-A antibody D5 VH domain (SEQ ID NO: 51) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 53 is substituted for the VH CDR1 of H1.
- [0175]** The amino acid sequence of the anti-ED-A antibody E5 VH domain (SEQ ID NO: 61) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 63 is substituted for the VH CDR1 of H1.
- 30 **[0176]** The amino acid sequence of the anti-ED-A antibody C8 VH domain (SEQ ID NO: 71) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 73 is substituted for the VH CDR1 of H1.
- [0177]** The amino acid sequence of the anti-ED-A antibody F8 VH domain (SEQ ID NO: 81) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 83 is substituted for the VH CDR1 of H1. The VH domain of the anti-ED-A F8 diabody has the same amino acid sequence as VH domain of the anti-ED-A antibody F8 (i.e. SEQ ID NO: 81).
- 35 **[0178]** The amino acid sequence of the anti-ED-A antibody F1 VH domain (SEQ ID NO: 91) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 93 is substituted for the VH CDR1 of H1.
- [0179]** The amino acid sequence of the anti-ED-A antibody B7 VH domain (SEQ ID NO: 101) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 103 is substituted for the VH CDR1 of H1.
- 40 **[0180]** The amino acid sequence of the anti-ED-A antibody E8 VH domain (SEQ ID NO: 111) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 113 is substituted for the VH CDR1 of H1.
- 45 **[0181]** The amino acid sequence of the anti-ED-A antibody G9 VH domain (SEQ ID NO: 31) is identical to the amino acid sequence of the VH domain of anti-ED-A antibody H1 except that SEQ ID NO: 33 is substituted for the VH CDR1 of H1.
- [0182]** The amino acid sequence of the anti-ED-A antibody B2 VL domain (SEQ ID NO: 22) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 26 is substituted for the VL CDR1 of H1.
- [0183]** The amino acid sequence of the anti-ED-A antibody C5 VL domain (SEQ ID NO: 42) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 46 is substituted for the VL CDR1 of H1.
- 50 **[0184]** The amino acid sequence of the anti-ED-A antibody D5 VL domain (SEQ ID NO: 52) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 56 is substituted for the VL CDR1 of H1.
- [0185]** The amino acid sequence of the anti-ED-A antibody E5 VL domain (SEQ ID NO: 62) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 66 is substituted for the VL CDR1 of H1.
- 55 **[0186]** The amino acid sequence of the anti-ED-A antibody C8 VL domain (SEQ ID NO: 72) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 76 is substituted for the VL CDR1 of H1.
- [0187]** The amino acid sequence of the anti-ED-A antibody F8 VL domain (SEQ ID NO: 82) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 86 is substituted for the VL CDR1

of H1. The VL domain of the anti-ED-A F8 diabody has the same amino acid sequence as VL domain of the anti-ED-A antibody F8 (i.e. SEQ ID NO: 82).

[0188] The amino acid sequence of the anti-ED-A antibody F1 VL domain (SEQ ID NO: 92) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 96 is substituted for the VL CDR1 of H1.

[0189] The amino acid sequence of the anti-ED-A antibody B7 VL domain (SEQ ID NO: 102) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 106 is substituted for the VL CDR1 of H1.

[0190] The amino acid sequence of the anti-ED-A antibody E8 VL domain (SEQ ID NO: 112) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 116 is substituted for the VL CDR1 of H1.

[0191] The amino acid sequence of the anti-ED-A antibody G9 VL domain (SEQ ID NO: 32) is identical to the amino acid sequence of the VL domain of anti-ED-A antibody H1 except that SEQ ID NO: 36 is substituted for the VL CDR1 of H1.

[0192] Optionally, the amino acid at position 5 of the VH domain of anti-ED-A antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8, G9 and the scFv F8 diabody may be a leucine residue (L) rather than a valine residue (V) as shown in Figure 4A. In addition, or alternatively, the amino acid at position 18 of the VL domain of anti-ED-A antibodies H1, B2, C5, D5, E5, C8, F8, F1, B7, E8, G9 and the scFv F8 diabody may be an arginine residue (R) rather than a lysine residue (K) as shown in Figure 4C.

Cloning, Production and Characterization of F8-IL10

[0193] The human IL-10 gene was amplified by PCR using the following primer sequences:

a backward antisense primer,

5'-TCGGGTAGTAGCTCTTCCGGCTCATCGTCCAGCGGCAGCCCAGGCCAGGGCACC-3';

and a forward sense primer,

5'-TTTTCTTTTGCGCGCCGCtattaGTTTCGTATCTTCATTGTCATGTA-3',

which appended part of a 15 amino acid linker (SSSSG)₃ at its N-terminal and stop codon and NotI restriction site at its C-terminal.

[0194] DNA encoding the single-chain variable fragment (F8) was amplified with a signal peptide using the following primer pairs:

a backward antisense primer,

5'-CCCAAGCTTGTGACCATGGGCTGGAGCC-3'

and a forward sense primer,

5' -

GAGCCGGAAGAGCTACTACCCGATGAGGAAGAGAATTCTTTGATTTCCACCTTGGTCCCTTG-

3' .

[0195] Using this strategy, a HindIII restriction site was inserted at the N-terminal and a complementary part of the linker sequence was inserted at the C-terminal.

[0196] The single-chain Fv and IL-10 fragments were then assembled using PCR and cloned into the HindIII and NotI restriction sites of the mammalian cell-expression vector pcDNA3.1(+).

[0197] CHO-S cells were stably transfected with the previously described plasmids and selection was carried out in the presence of G418 (0.5 g/l).

[0198] Clones of G418-resistant cells were screened for expression of the fusion protein by ELISA using a recombinant EDA of human fibronectin as antigens and Protein A for detection.

[0199] The fusion proteins were purified from the cell-culture medium by affinity chromatography over Protein A columns.

[0200] The size of the fusion proteins was analysed in reducing and nonreducing conditions on SDS-PAGE and in native conditions by FPLC gel filtration on a Superdex S-200 exclusion column (Amersham Pharmacia Biotech, Dübendorf, Switzerland).

Activity Assay

[0201] Biological activity of hIL10 was determined by its ability to induce the IL-4 dependent proliferation of MC/9 cells

(Thompson-et al., 1991) using the colorimetric MTT dye-reduction assay.

[0202] 10.000 MC/9 (ATCC, Manassas, USA) cells/ well in 200 μ l of medium containing 5 pg (0.05 Units) of murine IL4 /ml (eBiosciences) in a 96-well microtiter plate were treated for 48 hr with varying amounts of human IL10. The hIL10 standard and the F8-IL10 fusion protein were used at a maximum of 100 ng / ml IL10 equivalents and serially diluted. 10 μ l of 5 mg/ml MTT (Sigma) was added and incubated for 3-5 hr. The cells were then centrifuged, lysed with DMSO and read for absorbance at 570 nm.

REFERENCES

[0203]

- Amit et al. (1986), *Science*, 233:747-753.
- Andersen et al. (2002) *Current Opinion in Biotechnology* 13: 117
- Ausubel et al. (1999) 4th eds., *Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology*, John Wiley & Sons.
- Bagshawe K.D. et al. (1991) *Antibody, Immunoconjugates and Radiopharmaceuticals* 4: 915-922
- Balza et al. (1988), *FEBS Lett.*, 228: 42-44.
- Batista et al. *J. Exp. Med.*, 184: 2197-205, 1996.
- Berndt et al. *Histochem Cell Biol* 1998, 109(3) :249-255.
- Birchler et al. (1999), *J. Immunol. Methods*, 231, 239-248.
- Bird et al. (1988) *Science*, 242, 423-426
- Borsi et al. (1987), *J. Cell. Biol.*, 104, 595-600.
- Borsi et al. (1990), *FEBS Lett.*, 261: 175-178.
- Borsi et al. (1995), *J. Biol.Chem.*, 270: 6243-6245.
- Borsi et al. (1998), *Exp. Cell Res.*, 240, 244-251.
- Borsi et al. (2000) *Int J Cancer*, 102(1):75-85.
- Brack et al. (2006), *Clin. Cancer Res.*, 12, 3200-3208.
- Carnemolla et al. (1989), *J. Cell. Biol.*, 108: 1139-1148.
- Caton et al. (1990), *J. Immunol.*, 144:1965-1968.
- Chadd et al. (2001), *Current Opinion in Biotechnology* 12: 188-194
- Chothia et al. (1987), *J. Mol. Biol.*, 196:901-917.
- Chothia et al. (1989), *Nature*, 342:877- 883.
- Courtney et al. (1980) *Nature*, 14;283(5748):666-8.
- Devos et al. (1983), *Nucl. Acids Res.* 11: 4307-4323.
- French-Constant (1995), *Exp. Cell Res.*, 221, 261-271.
- Giovannoni, *Nucleic. Acid Research*, 2001, 29(5):E27.
- Glennie M J et al., 1987 *J. Immunol.* 139, 2367-2375
- Haan et al. (2004), *BioCentury*, 12(5): A1-A6.
- Hanahan et al. (2000), *Cell* 100, 57-70.
- Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor N.Y., pp. 726, 1988
- Heikinheimo et al. (1991), *Virchows Arch. B Cell Pathol. Incl. Mol. Pathol.*, 61, 101-109.
- Holliger and Bohlen 1999 *Cancer and metastasis rev.* 18: 411-419.
- Holliger et al. (1993a), *Proc. Natl. Acad. Sci. USA* 90 6444-6448.
- Holliger et al. (1993b), *Current Opinion Biotechnol* 4, 446-449.
- Holt et al. (2003) *Trends in Biotechnology* 21, 484-490.
- Hoogenboom et al. (1991), *Nucleic Acids Res.*, 19 (15) 4133-7.
- Hu et al. (1996), *Cancer Res.*, 56, 3055-3061.
- Huston et al. (1988) *PNAS USA*, 85, 5879-5883.
- Hynes, R.O. (1990). *Fibronectins* (New York: Springer-Verlag).
- Jacobs et al. (2002), *Hum. Pathol.*, 33, 29-38.
- Kabat et al. (1987) *Sequences of Proteins of Immunological Interest*. 4th Edition. US Department of Health and Human Services.
- Kabat et al. (1991a), *Sequences of Proteins of Immunological Interest*, 5th Edition. US Department of Health and Human Services, Public Service, NIH, Washington. (a)
- Kabat et al. (1991b), *J. Immunol.*, 147:1709-1719.
- Kaspar et al. (2006), *Int. J. Cancer*, 118, 1331-1339.
- Knappik et al., (2000) *J. Mol. Biol.* 296, 57-86.

- Koch et al. *Ann Rheum Dis* 2003, 62 Suppl 2:ii60-67.
Kohler and Milstein, *Nature*, 256:495-497, 1975
Koide et al. (1998), *Journal of Molecular Biology*, 284: 1141-1151.
Kontermann et al. (2001), *S, Antibody Engineering*, Springer-Verlag New York, LLC; ISBN: 3540413545.
5 Kornblihtt et al. (1984), *Nucleic Acids Res.* 12, 5853-5868.
Koukoulis et al. (1993), *J. Submicrosc. Cytol. Pathol.*, 25, 285-295.
Koukoulis et al. (1995), *Ultrastruct. Pathol.*, 19, 37-43.
Krebs et al. (2001), *Journal of Immunological Methods*, 254 67-84. Kriegsmann et al.(2004) *Rheumatol Int*,
24(1):25-33.
10 Larrick JW and Thomas DW (2001) *Current Opinion in Biotechnology* 12:411-418.
Ledermann J.A. et al. (1991) *Int. J. Cancer* 47: 659-664
Li et al. *Protein Engineering*, 10: 731-736, 1997
Lohi et al. (1995), *Int. J. Cancer*, 63, 442-449.
Maeda et al. (1983) *Biochem. Biophys. Res. Comm.* 115: 1040-1047;
15 Matsumoto et al. (1999), *Jpn. J. Cancer Res.*, 90, 320-325.
McCafferty et al., (1990) *Nature*, 348, 552-554.
Mendez, M. et al., (1997) *Nature Genet*, 15(2): 146-156.
Merchand et al., 1998 *Nature Biotech.* 16:677-681
Neri, D., and Bicknell, R. (2005), *Nat Rev Cancer* 5, 436-446.
20 Nygren et al. (1997), *Current Opinion in Structural Biology*, 7: 463-469.
Oyama et al. (1989), *J. Biol. Chem.*, 264, 10331-10334.
Paolella et al. (1988), *Nucleic Acids Res.* 16, 3545-3557.
Pini et al. (1998), *J. Biol. Chem.*, 273, 21769-21776.
Pluckthun (1991), *Bio/Technology* 9: 545-551.
25 Reiter et al. (1996), *Nature Biotech.* 14, 1239-1245.
Repp et al., 1995 *J. Hemat.* 377-382.
Ridgeway et al. (1996), *Protein Eng.*, 9, 616-621.
Robinson ed., *Sustained and Controlled Release Drug Delivery Systems*, Marcel Dekker, Inc., New York, 1978
Roesli et al. (2006), *Nature Protocols*, 1, 192-199.
30 Ruf et al. (1991) *J. Biol. Chem.* 226: 15719-15725.
Rybak et al. (2005), *Nat. Methods*, 2, 291-298.
Rybak et al. (2006), *ChemMedChem.*, 2,22-40.
Sambrook and Russell, *Molecular Cloning: a Laboratory Manual: 3rd edition*, 2001, Cold Spring Harbor Laboratory
Press
35 Scarpati et al. (1987) *Biochemistry* 26: 5234-5238.
Scarpino et al. (1999) *J. Pathol.* 188, 163-167.
Scheurer et al. (2005), *Proteomics* 5, 3035-3039.
Segal et al. (1974), *PNAS*, 71:4298-4302.
Sharon et al. (1990a), *PNAS*, 87:4814-4817.
40 Sharon et al. (1990b), *J. Immunol.*, 144:4863-4869.
Silacci et al. (2003), *Proteomics*, 5, 2340-2350.
Staerz U. D. and Bevan M. J. 1986 *PNAS* 83
Suresh et al. (1986) *Method Enzymol.* 121: 210-228
Taniguchi et al. (1983) *Nature* 302, 305-310;
45 Tarli et al. *Blood* 1999, 94(1):192-198.
Tavian et al. (1994), *Int. J. Cancer*, 56, 820-825.
Taylor, *Arthritis Res* 2002, 4 Suppl 3:S99-107.
Terrana et al. (1987), *Cancer Res.* 47, 3791-3797.
Thompson et al. (1991), *J Exp Med*, 173:507-510.
50 Thorpe (2004), *Clin. Cancer Res.*, 10, 415-427.
Trachsel et al. (2006), *Adv. Drug Deliv. Rev.*, 58, 735-754.
Trachsel et al. *Arthritis Res Ther* 2007, 9(1):R9.
Viti et al. (2000), *Methods Enzymol.*, 326, 480-505.
Walsh et al. (1998) *Am J Pathol*, 152(3):691-702.
55 Ward et al. (1989), *Nature* 341, 544-546.
Wess In: *BioCentury, The Bernstein Report on BioBusiness*, 12(42), A1-A7, 2004.

EP 3 281 952 B1

TABLE 1

Nucleotide and amino acid sequences of the heavy chain (VH) and light chain (VL) CDR1s of the anti-ED-A affinity matured antibodies

Antibody	CDR1 (VH)	CDR1 (VL)
H1	CCG CGG AGG P R R (SEQ ID NO: 3)	TCT GCG TGG S A W (SEQ ID NO: 6)
B2	GCG GCT AAG A A K (SEQ ID NO: 23)	GTG GCT TTT V A F (SEQ ID NO: 26)
C5	CCG ATT ACT P I T (SEQ ID NO: 43)	TTG CAT TTT L H F (SEQ ID NO: 46)
D5	GTG ATG AAG V M K (SEQ ID NO: 53)	AAT GCT TTT N A F (SEQ ID NO: 56)
E5	ACT GGT TCT T G S (SEQ ID NO: 63)	CTT GCG CAT L A H (SEQ ID NO: 66)
C8	CTT CAG ACT L Q T (SEQ ID NO: 73)	CTT CCT TTT L P F (SEQ ID NO: 76)
F8	CTG TTT ACG L F T (SEQ ID NO: 83)	ATG CCG TTT M P F (SEQ ID NO: 86)
F1	TAG GCG CGT Q (Amber) A R (SEQ ID NO: 93)	GCG CCT TTT A P F (SEQ ID NO: 96)
B7	CAT TTT GAT H F D (SEQ ID NO: 103)	CTG GCT TTT L A F (SEQ ID NO: 106)
E8	GAT ATG CAT D M H (SEQ ID NO: 113)	TCG TCT TTT S S F (SEQ ID NO: 116)
G9	CAT ATG CAG H M Q (SEQ ID NO: 33)	ACT GCT TTT T A F (SEQ ID NO: 36)

TABLE 2

<i>BIAcore evaluation data</i>			
Antibody	k_{on} (1/Ms)	k_{off} (1/s)	K_D (M)
Parent anti-ED-A antibody	2.5×10^5	0.02	$\sim 1 \times 10^{-7}$
B2	3.8×10^5	7.54×10^{-3}	$\sim 2 \times 10^{-8}$
C5	3.04×10^5	9.23×10^{-3}	$\sim 3 \times 10^{-8}$
D5	4.53×10^5	7.6×10^{-3}	$\sim 1.7 \times 10^{-8}$
C8	3.8×10^5	5.3×10^{-3}	$\sim 1.4 \times 10^{-8}$
F8	4.65×10^5	1.4×10^{-3}	$\sim 3.1 \times 10^{-9}$
B7	2.67×10^5	4.5×10^{-3}	$\sim 1.68 \times 10^{-8}$
G9	3.6×10^5	7.54×10^{-3}	$\sim 2.09 \times 10^{-8}$

SEQUENCE LISTING

[0204]

EP 3 281 952 B1

<110> Philogen S.p.A. KASPAR, Manuela SCHWAGER, Kathrin TRACHSEL, Eveline

<120> An Antigen Associated With Rheumatoid Arthritis

5 <130> SMWFP6580872

<150> US 60/983,606

<151> 2007-10-30

10 <160> 147

<170> PatentIn version 3.3

<210> 1

15 <211> 118

<212> PRT

<213> Artificial sequence

<220>

20 <223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody H1 heavy chain (VH)

<400> 1

25 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Pro Arg
30 20 25 30

 Arg Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

35 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

40 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
45 85 90 95

 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

50 Leu Val Thr Val Ser Ser
 115

<210> 2

55 <211> 125

<212> PRT

<213> Artificial sequence

EP 3 281 952 B1

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody H1 light chain (VL)

<400> 2

5

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

10

Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ala
20 25 30

15

Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

20

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

25

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

30

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110

35

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

<210> 3

<211> 3

<212> PRT

<213> Artificial sequence

40

<220>

<223> Synthetic sequence: Amino acid sequence of the heavy chain CDR1 of anti-ED-A antibody H1

<400> 3

45

Pro Arg Arg
1

50

<210> 4

<211> 6

<212> PRT

<213> Artificial sequence

55

<220>

<223> Synthetic sequence: Amino acid sequence of the heavy chain CDR2 of anti-ED-A antibody H1

<400> 4

EP 3 281 952 B1

Ser Gly Ser Gly Gly Ser
1 5

5 <210> 5
<211> 6
<212> PRT
<213> Artificial sequence

10 <220>
<223> Synthetic sequence: Amino acid sequence of the heavy chain CDR3 of anti-ED-A antibody H1
<400> 5

15 Ser Thr His Leu Tyr Leu
1 5

<210> 6
<211> 3
<212> PRT
20 <213> Artificial sequence

<220>
<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody H1
25 <400> 6

Ser Ala Trp
1

30 <210> 7
<211> 7
<212> PRT
<213> Artificial sequence

35 <220>
<223> Synthetic sequence: Amino acid sequence of the light chain CDR2 of anti-ED-A antibody H1
<400> 7

40 Gly Ala Ser Ser Arg Ala Thr
1 5

<210> 8
<211> 6
45 <212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence: Amino acid sequence of the light chain CDR3 of anti-ED-A antibody H1
50 <400> 8

55 Met Arg Gly Arg Pro Pro
1 5

<210> 9
<400> 9

EP 3 281 952 B1

000

<210> 10

5 <400> 10
000

<210> 11
<211> 20
10 <212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody H1 linker sequence

15 <400> 11

20 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15

Gly Gly Gly Ser
20

25 <210> 12
<211> 354
<212> DNA
<213> Artificial sequence

30 <220>
<223> Synthetic sequence: Nucleotide sequence of the anti-ED-A antibody H1 heavy chain (VH)

<400> 12

35 gaggtgcagc tgggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt caccttagc ccgcggagga tgagctgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac 180
40 gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaaagtact 300
45 catttgtatc tttttgacta ctggggccag ggaaccctgg tcaccgtctc gagt 354

<210> 13
<211> 387
<212> DNA
50 <213> Artificial sequence

<220>
<223> Synthetic sequence: Nucleotide sequence of the anti-ED-A antibody H1 light chain (VL)

55 <400> 13

EP 3 281 952 B1

gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aaaagccacc 60
 ctctcctgca gggccagtca gagtgtagc tctgcgtggt tagcctggta ccagcagaaa 120
 5 cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180
 gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag 240
 cctgaagatt ttgcagtgta ttactgtcag cagatgctgt gtcggccgcc gacgttcggc 300
 10 caagggacca aggtggaaat caaagcggcc gcagaacaaa aactcatctc agaagaggat 360
 ctgaatgggg cgcgatagac tgtgaaa 387

15 <210> 14
 <211> 60
 <212> DNA
 <213> Artificial sequence

20 <220>
 <223> Synthetic sequence: Nucleotide sequence of the anti-ED-A antibody H1 linker sequence

<400> 14
 25 ggcggtggag gttctggcgg cggtggcagt ggcggtggag gttccggggg tggaggatct 60

<210> 15
 <211> 17
 <212> PRT
 <213> Mus musculus

30 <400> 15

35 Phe Leu Thr Thr Thr Pro Asn Ser Leu Leu Val Ser Trp Gln Ala Pro
 1 5 10 15

Arg

40 <210> 16
 <211> 12
 <212> PRT
 <213> Mus musculus

45 <400> 16

Ile Ala Trp Glu Ser Pro Gln Gly Gln Val Ser Arg
 1 5 10

50 <210> 17
 <211> 52
 <212> DNA
 <213> Artificial sequence

55 <220>
 <223> Synthetic sequence: Partially degenerate primer

<220>
 <221> misc_feature

EP 3 281 952 B1

<222> (27)..(28)
<223> n is a or g or c or t

5 <220>
<221> misc_feature
<222> (30)..(31)
<223> n is a or g or c or t

10 <220>
<221> misc_feature
<222> (33)..(34)
<223> n is a or g or c or t

15 <400> 17
ctggagcctg gcggaccag ctcatmnmn nmngctaaa ggtgaatcca ga 52

20 <210> 18
<211> 58
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence: Partially degenerate primer

25 <220>
<221> misc_feature
<222> (28)..(29)
<223> n is a or g or c or t

30 <220>
<221> misc_feature
<222> (31)..(32)
<223> n is a or g or c or t

35 <220>
<221> misc_feature
<222> (34)..(35)
<223> n is a or g or c or t

40 <400> 18
ccaggttct gctgtacca ggctaamnm nmngctaa cactctgact ggcctgc 58

45 <210> 19
<211> 26
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence: Primer LMB3long

50 <400> 19
caggaaacag ctatgacat gattac 26

55 <210> 20
<211> 30
<212> DNA
<213> Artificial sequence

EP 3 281 952 B1

<220>

<223> Synthetic sequence: Primer fdseqlong

<400> 20

5 gacgtagta aatgaattt ctgtatgagg 30

<210> 21

<211> 118

<212> PRT

10 <213> Artificial sequence

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody B2 VH domain

15 <400> 21

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

20

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Ala
20 25 30

25

Lys Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

30

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

35

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

40

Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

45

Leu Val Thr Val Ser Ser
115

<210> 22

<211> 125

<212> PRT

50 <213> Artificial sequence

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody B2 VL domain

55 <400> 22

EP 3 281 952 B1

<220>

<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody B2

<400> 26

5

Val Ala Phe
1

<210> 27

10

<400> 27
000

<210> 28

15

<211> 5
<212> PRT
<213> Artificial sequence

<220>

20

<223> Synthetic sequence: Linker sequence of F8 diabody

<400> 28

25

Gly Ser Ser Gly Gly
1 5

<210> 29

<211> 15

<212> DNA

30

<213> Artificial sequence

<220>

<223> Synthetic sequence: Linker sequence of F8 diabody

35

<400> 29
gggtccagtg gcggt 15

<210> 30

40

<400> 30
000

<210> 31

<211> 118

45

<212> PRT
<213> Artificial sequence

<220>

50

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody G9 VH domain

<400> 31

55

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

EP 3 281 952 B1

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Met
 20 25 30
 5
 Gln Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 10
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60
 15
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 20
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 25
 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Leu Val Thr Val Ser Ser
 115

<210> 32

<211> 125

<212> PRT

30 <213> Artificial sequence

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody G9 VL domain

35 <400> 32

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 40
 Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ala
 20 25 30
 45
 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 50
 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 55
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
 85 90 95

EP 3 281 952 B1

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110

5 Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

<210> 33

<211> 3

10 <212> PRT

<213> Artificial sequence

<220>

15 <223> Synthetic sequence: Amino acid sequence of the heavy chain CDR1 of anti-ED-A antibody G9

<400> 33

His Met Gln

1

20

<210> 34

<400> 34

000

25

<210> 35

<400> 35

000

30

<210> 36

<211> 3

<212> PRT

<213> Artificial sequence

35

<220>

<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody G9

<400> 36

40

Thr Ala Phe

1

45

<210> 37

<400> 37

000

50

<210> 38

<400> 38

000

55

<210> 39

<400> 39

000

EP 3 281 952 B1

<210> 40

<400> 40
000

5

<210> 41

<211> 118

<212> PRT

<213> Artificial sequence

10

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody C5 VH domain

<400> 41

15

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

20

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Pro Ile
20 25 30

25

Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

30

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

35

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

40

Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

45

Leu Val Thr Val Ser Ser
115

<210> 42

<211> 125

<212> PRT

<213> Artificial sequence

50

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody C5 VL domain

<400> 42

55

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

EP 3 281 952 B1

Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Leu His
 20 25 30
 5 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 10 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 15 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
 85 90 95
 20 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
 100 105 110
 25 Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
 115 120 125

<210> 43
 <211> 3
 <212> PRT
 30 <213> Artificial sequence
 <220>
 <223> Synthetic sequence: Amino acid sequence of the heavy chain CDR1 of anti-ED-A antibody C5
 35 <400> 43
 Pro Ile Thr
 1
 40 <210> 44
 <400> 44
 000
 45 <210> 45
 <400> 45
 000
 50 <210> 46
 <211> 3
 <212> PRT
 <213> Artificial sequence
 55 <220>
 <223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody C5
 <400> 46

EP 3 281 952 B1

Leu His Phe
1

5 <210> 47
<400> 47
000

10 <210> 48
<400> 48
000

15 <210> 49
<400> 49
000

20 <210> 50
<400> 50
000

25 <210> 51
<211> 118
<212> PRT
<213> Artificial sequence

30 <220>
<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody D5 VH domain

<400> 51

35 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Met
 20 25 30

40 Lys Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

50 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

55 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

EP 3 281 952 B1

Leu Val Thr Val Ser Ser
115

5 <210> 52
<211> 125
<212> PRT
<213> Artificial sequence

10 <220>
<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody D5 VL domain

<400> 52

15 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
20 Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Ala
20 25 30
25 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45
30 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60
35 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
40 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
85 90 95
45 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110
50 Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

45 <210> 53
<211> 3
<212> PRT
<213> Artificial sequence

50 <220>
<223> Synthetic sequence: Amino acid sequence of the heavy chain CDR1 of anti-ED-A antibody D5

<400> 53

55 Val Met Lys
1

<210> 54

EP 3 281 952 B1

<400> 54
000

5 <210> 55

<400> 55
000

10 <210> 56
<211> 3
<212> PRT
<213> Artificial sequence

15 <220>
<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody D5

<400> 56

20 **Asn Ala Phe**
1

<210> 57

25 <400> 57
000

<210> 58

30 <400> 58
000

<210> 59

35 <400> 59
000

<210> 60

40 <400> 60
000

<210> 61
<211> 118
<212> PRT
45 <213> Artificial sequence

<220>
<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody E5 VH domain

50 <400> 61

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

55 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Gly
20 25 30

EP 3 281 952 B1

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

5 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

10 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

15 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

20 Leu Val Thr Val Ser Ser
115

<210> 62
<211> 125
25 <212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody E5 VL domain
30 <400> 62

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
35

Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Leu Ala
20 25 30
40

His Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80
50

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
85 90 95
55

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110

EP 3 281 952 B1

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

5 <210> 63
<211> 3
<212> PRT
<213> Artificial sequence

10 <220>
<223> Synthetic sequence: Amino acid sequence of the heavy chain CDR1 of anti-ED-A antibody E5

<400> 63

15 Thr Gly Ser
1

<210> 64

20 <400> 64
000

<210> 65

25 <400> 65
000

30 <210> 66
<211> 3
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody E5

35 <400> 66

Leu Ala His
1

40 <210> 67

<400> 67
000

45 <210> 68

<400> 68
000

50 <210> 69

<400> 69
000

55 <210> 70

<400> 70
000

EP 3 281 952 B1

<210> 71
 <211> 118
 <212> PRT
 <213> Artificial sequence

5

<220>
 <223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody C8 VH domain

<400> 71

10

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Leu Gln
 20 25 30

20

Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

25

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

30

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

35

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

40

<210> 72
 <211> 125
 <212> PRT
 <213> Artificial sequence

45

<220>
 <223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody C8 VL domain

<400> 72

50

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

55

Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Leu Pro
 20 25 30

EP 3 281 952 B1

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

5 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

10 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

15 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
85 90 95

20 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

<210> 73

<211> 3

25 <212> PRT

<213> Artificial sequence

<220>

30 <223> Synthetic sequence: Amino acid sequence of the heavy chain CDR1 of anti-ED-A antibody C8

<400> 73

Leu Gln Thr

1

35

<210> 74

<400> 74

000

40

<210> 75

<400> 75

000

45

<210> 76

<211> 3

<212> PRT

<213> Artificial sequence

50

<220>

<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody C8

<400> 76

55

Leu Pro Phe

5 <210> 77
 <400> 77
 000

10 <210> 78
 <400> 78
 000

15 <210> 79
 <400> 79
 000

20 <210> 80
 <400> 80
 000

25 <210> 81
 <211> 118
 <212> PRT
 <213> Artificial sequence

30 <220>
 <223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody F8 VH domain

 <400> 81

35

40

45

50

55

EP 3 281 952 B1

<220>

<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody F8

<400> 86

5

Met Pro Phe
1

<210> 87

10

<400> 87
000

<210> 88

15

<400> 88
000

<210> 89

20

<400> 89
000

<210> 90

25

<400> 90
000

<210> 91

30

<211> 118
<212> PRT
<213> Artificial sequence

<220>

35

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody F1 VH domain

<400> 91

40

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

45

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gln Ala
20 25 30

50

Arg Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

55

EP 3 281 952 B1

35

40

45

5 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

10 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

15 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
100 105 110

20 Leu Val Thr Val Ser Ser
115

<210> 92

<211> 125

<212> PRT

25 <213> Artificial sequence

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody F1 VL domain

30 <400> 92

35

40

45

50

55

EP 3 281 952 B1

<213> Artificial sequence

<220>

<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody F1

5

<400> 96

Ala Pro Phe

1

10

<210> 97

<400> 97

000

15

<210> 98

<400> 98

000

20

<210> 99

<400> 99

000

25

<210> 100

<400> 100

000

30

<210> 101

<211> 118

<212> PRT

<213> Artificial sequence

35

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody B7 VH domain

<400> 101

40

45

50

55

EP 3 281 952 B1

1 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 5 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Phe
 10 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 15 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 20 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 25 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 30 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 35 Leu Val Thr Val Ser Ser
 40

<210> 102

<211> 125

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody B7 VL domain

<400> 102

1 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 5 Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Leu Ala
 10 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

EP 3 281 952 B1

		35		40		45										
5	Ile	Tyr	Gly	Ala	Ser	Ser	Arg	Ala	Thr	Gly	Ile	Pro	Asp	Arg	Phe	Ser
		50					55					60				
10	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Arg	Leu	Glu
	65					70					75					80
15	Pro	Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	Gln	Met	Arg	Gly	Arg	Pro
					85					90					95	
20	Pro	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Ala	Ala	Ala	Glu
			100						105					110		
	Gln	Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu	Asn	Gly	Ala	Ala			
			115					120					125			

<210> 103

<211> 3

<212> PRT

25 <213> Artificial sequence

<220>

<223> Synthetic sequence: Amino acid sequence of the heavy chain CDR1 of anti-ED-A antibody B7

30 <400> 103

His Phe Asp

1

35 <210> 104

<400> 104

000

40 <210> 105

<400> 105

000

45 <210> 106

<211> 3

<212> PRT

<213> Artificial sequence

50 <220>

<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody B7

<400> 106

55 Leu Ala Phe

1

<210> 107

EP 3 281 952 B1

<400> 107
000

5 <210> 108

<400> 108
000

10 <210> 109

<400> 109
000

15 <210> 110

<400> 110
000

20 <210> 111
<211> 118
<212> PRT
<213> Artificial sequence

25 <220>
<223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody E8 VH domain

<400> 111

30 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Met
35 20 25 30

 His Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

40 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

45 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
50 85 90 95

 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

55 Leu Val Thr Val Ser Ser
 115

EP 3 281 952 B1

<210> 112
 <211> 125
 <212> PRT
 <213> Artificial sequence

5

<220>
 <223> Synthetic sequence: Amino acid sequence of the anti-ED-A antibody E8 VL domain

<400> 112

10

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

15

Glu Lys Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30

20

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

25

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60

30

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80

35

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
 85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
 100 105 110

40

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
 115 120 125

<210> 113
 <211> 3
 <212> PRT
 <213> Artificial sequence

45

<220>
 <223> Synthetic sequence: Amino acid sequence of the heavy chain CDR1 of anti-ED-A antibody E8

<400> 113

50

Asp Met His
 1

55

<210> 114
 <400> 114
 000

EP 3 281 952 B1

<210> 115

<400> 115
000

5

<210> 116
<211> 3
<212> PRT
<213> Artificial sequence

10

<220>
<223> Synthetic sequence: Amino acid sequence of the light chain CDR1 of anti-ED-A antibody E8

<400> 116

15

Ser Ser Phe
1

<210> 117

20

<400> 117
000

<210> 118
<211> 90
<212> PRT
<213> Homo sapiens

25

<400> 118

30

Asn	Ile	Asp	Arg	Pro	Lys	Gly	Leu	Ala	Phe	Thr	Asp	Val	Asp	Val	Asp
1				5					10					15	

Ser	Ile	Lys	Ile	Ala	Trp	Glu	Ser	Pro	Gln	Gly	Gln	Val	Ser	Arg	Tyr
		20						25					30		

Arg	Val	Thr	Tyr	Ser	Ser	Pro	Glu	Asp	Gly	Ile	His	Glu	Leu	Phe	Pro
		35					40					45			

Ala	Pro	Asp	Gly	Glu	Glu	Asp	Thr	Ala	Glu	Leu	Gln	Gly	Leu	Arg	Pro
	50					55					60				

Gly	Ser	Glu	Tyr	Thr	Val	Ser	Val	Val	Ala	Leu	His	Asp	Asp	Met	Glu
65					70					75					80

Ser	Gln	Pro	Leu	Ile	Gly	Thr	Gln	Ser	Thr
				85				90	

<210> 119
<211> 90
<212> PRT
<213> Mus musculus

55

<400> 119

EP 3 281 952 B1

1 Asn Ile Asp Arg Pro Lys Gly Leu Ala Phe Thr Asp Val Asp Val Asp
 5 Ser Ile Lys Ile Ala Trp Glu Ser Pro Gln Gly Gln Val Ser Arg Tyr
 10 Arg Val Thr Tyr Ser Ser Pro Glu Asp Gly Ile Arg Glu Leu Phe Pro
 15 Ala Pro Asp Gly Glu Asp Asp Thr Ala Glu Leu Gln Gly Leu Arg Pro
 20 Gly Ser Glu Tyr Thr Val Ser Val Val Ala Leu His Asp Asp Met Glu
 25 Ser Gln Pro Leu Ile Gly Ile Gln Ser Thr
 <210> 120
 <211> 288
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> Synthetic sequence: Antigen (11A12) containing the ED-A domain of human fibronectin
 <400> 120
 35 Met Arg Ser Tyr Arg Thr Glu Ile Asp Lys Pro Ser Gln Met Gln Val
 40 Thr Asp Val Gln Asp Asn Ser Ile Ser Val Lys Trp Leu Pro Ser Ser
 45 Ser Pro Val Thr Gly Tyr Arg Val Thr Thr Thr Pro Lys Asn Gly Pro
 50 Gly Pro Thr Lys Thr Lys Thr Ala Gly Pro Asp Gln Thr Glu Met Thr
 55 Ile Glu Gly Leu Gln Pro Thr Val Glu Tyr Val Val Ser Val Tyr Ala
 60 Gln Asn Pro Ser Gly Glu Ser Gln Pro Leu Val Gln Thr Ala Val Thr
 65 Asn Ile Asp Arg Pro Lys Gly Leu Ala Phe Thr Asp Val Asp Val Asp
 70 100 105 110

EP 3 281 952 B1

Ser Ile Lys Ile Ala Trp Glu Ser Pro Gln Gly Gln Val Ser Arg Tyr
 115 120 125
 5 Arg Val Thr Tyr Ser Ser Pro Glu Asp Gly Ile His Glu Leu Phe Pro
 130 135 140
 10 Ala Pro Asp Gly Glu Glu Asp Thr Ala Glu Leu Gln Gly Leu Arg Pro
 145 150 155 160
 15 Gly Ser Glu Tyr Thr Val Ser Val Val Ala Leu His Asp Asp Met Glu
 165 170 175
 Ser Gln Pro Leu Ile Gly Thr Gln Ser Thr Ala Ile Pro Ala Pro Thr
 180 185 190
 20 Asp Leu Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser Ala Gln Trp
 195 200 205
 25 Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg Val Thr Pro
 210 215 220
 30 Lys Glu Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala Pro Asp Ser
 225 230 235 240
 Ser Ser Val Val Val Ser Gly Leu Met Val Ala Thr Lys Tyr Glu Val
 245 250 255
 35 Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg Pro Ala Gln Gly
 260 265 270
 40 Val Val Thr Thr Leu Glu Asn Val Arg Ser His His His His His His
 275 280 285

<210> 121

<211> 867

<212> DNA

45 <213> Artificial sequence

<220>

<223> Synthetic sequence: Nucleotide sequence of antigen (11A12)

50 <400> 121

55

EP 3 281 952 B1

atgagatcct accgaacaga aattgacaaa ccatcccaga tgcaagtgac cgatgttcag 60
 gacaacagca ttagtgtcaa gtggctgcct tcaagttccc ctgttactgg ttacagagta 120
 5 accaccactc ccaaaaatgg accaggacca acaaaaacta aaactgcagg tccagatcaa 180
 acagaaatga ctattgaagg cttgcagccc acagtggagt atgtggttag tgtctatgct 240
 cagaatccaa gcggagagag tcagcctctg gttcagactg cagtaaccaa cattgatcgc 300
 10 cctaaaggac tggcattcac tgatgtggat gtcgattcca tcaaaattgc ttgggaaagc 360
 ccacaggggc aagtttccag gtacaggggtg acctactcga gccctgagga tggaatccat 420
 15 gagctattcc ctgcacctga tggatgaagaa gacactgcag agctgcaagg cctcagaccg 480
 ggttctgagt acacagtcag tgtggttgcc ttgcacgatg atatggagag ccagcccctg 540
 attggaacc agtccacagc tattcctgca ccaactgacc tgaagttcac tcaggtcaca 600
 20 cccacaagcc tgagcgccca gtggacacca cccaatgttc agctcactgg atatcgagtg 660
 cgggtgacct ccaaggagaa gaccggacca atgaaagaaa tcaaccttgc tcctgacagc 720
 25 tcatccgtgg ttgtatcagg acttatggtg gccaccaa atgaagtgag tgtctatgct 780
 cttaaggaca ctttgacaag cagaccagct caggagttg tcaccactct ggagaatgct 840
 agatctcatc accatcacca tcaactaa 867

30 <210> 122
 <211> 118
 <212> PRT
 <213> Artificial sequence

35 <220>
 <223> Synthetic sequence: VH domain of anti-ED-A antibody H1

<400> 122

40

45

50

55

EP 3 281 952 B1

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

5 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

10 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

15 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

20 <210> 125
 <211> 118
 <212> PRT
 <213> Artificial sequence

25 <220>
 <223> Synthetic sequence: VH domain of anti-ED-A antibody D5

<400> 125

30 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

35 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Val Met
 20 25 30

40 Lys Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

50 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

55 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

EP 3 281 952 B1

<210> 126
 <211> 118
 <212> PRT
 <213> Artificial sequence

5

<220>
 <223> Synthetic sequence: VH domain of anti-ED-A antibody E5

<400> 126

10

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Gly
 20 25 30

20

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

25

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

30

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

35

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

40

<210> 127
 <211> 118
 <212> PRT
 <213> Artificial sequence

45

<220>
 <223> Synthetic sequence: VH domain of anti-ED-A antibody C8

<400> 127

50

55

EP 3 281 952 B1

1 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 5 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Leu Gln
 10 Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 15 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 20 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 25 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 30 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 35 Leu Val Thr Val Ser Ser
 40
 45
 50
 55

<210> 128

<211> 118

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic sequence: VH domain of anti-ED-A antibody F8

<400> 128

EP 3 281 952 B1

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

5 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

10 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

15 Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

20 Leu Val Thr Val Ser Ser
 115

<210> 131
 <211> 118
 <212> PRT
 <213> Artificial sequence

25 <220>
 <223> Synthetic sequence: VH domain of anti-ED-A antibody E8

30 <400> 131

30 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

35 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Met
 20 25 30

40 His Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

50 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

55 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

EP 3 281 952 B1

<210> 132
 <211> 118
 <212> PRT
 <213> Artificial sequence

5

<220>
 <223> Synthetic sequence: VH domain of anti-ED-A antibody G9

<400> 132

10

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Met
 20 25 30

20

Gln Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

25

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

30

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

35

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Ser Thr His Leu Tyr Leu Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ser
 115

40

<210> 133
 <211> 125
 <212> PRT
 <213> Artificial sequence

45

<220>
 <223> Synthetic sequence: VL domain of anti-ED-A antibody H1

<400> 133

50

55

EP 3 281 952 B1

1 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 5 5 10 15
 5 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Val Ala
 20 25 30
 10 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 15 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 20 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 25 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
 85 90 95
 30 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
 100 105 110
 35 Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
 115 120 125

<210> 135

<211> 125

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic sequence: VL domain of anti-ED-A antibody C5

<400> 135

EP 3 281 952 B1

1 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 5 5 10 15
 5 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Leu His
 20 25 30
 10 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 15 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 15 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 20 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
 85 90 95
 25 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
 100 105 110
 30 Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
 115 120 125

30 <210> 136
 <211> 125
 <212> PRT
 <213> Artificial sequence
 35 <220>
 <223> Synthetic sequence: VL domain of anti-ED-A antibody D5
 40 <400> 136

40 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 45 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Ala
 20 25 30
 50 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

55

EP 3 281 952 B1

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

5 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

10 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
85 90 95

15 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

<210> 137
20 <211> 125
<212> PRT
<213> Artificial sequence

<220>
25 <223> Synthetic sequence: VL domain of anti-ED-A antibody E5

<400> 137

30 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Leu Ala
35 20 25 30

His Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

40 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

45 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

50 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
85 90 95

55 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

EP 3 281 952 B1

<210> 138
 <211> 125
 <212> PRT
 <213> Artificial sequence

5

<220>
 <223> Synthetic sequence: VL domain of anti-ED-A antibody C8

<400> 138

10

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Leu Pro
 20 25 30

20

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

25

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60

30

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
 85 90 95

35

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
 100 105 110

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
 115 120 125

40

<210> 139
 <211> 125
 <212> PRT
 <213> Artificial sequence

45

<220>
 <223> Synthetic sequence: VL domain of anti-ED-A antibody F8

<400> 139

50

55

EP 3 281 952 B1

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

5 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

10 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
85 90 95

15 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

<210> 143
20 <211> 125
<212> PRT
<213> Artificial sequence

<220>
25 <223> Synthetic sequence: VL domain of anti-ED-A antibody G9

<400> 143

30 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ala
35 20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

40 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

45 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

50 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Met Arg Gly Arg Pro
85 90 95

55 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ala Ala Glu
100 105 110

Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
115 120 125

EP 3 281 952 B1

<210> 144
<211> 54
<212> DNA
<213> Artificial sequence
5
<220>
<223> Synthetic sequence: Primer

<400> 144
10 tcggttagta gctcttcgg ctcatcgtcc agcggcagcc caggccaggg cacc 54

<210> 145
<211> 48
<212> DNA
15 <213> Artificial sequence

<220>
<223> Synthetic sequence: Primer

20 <400> 145
tttcctttt gcggccgctc attagttcg tatctcatt gtcattga 48

<210> 146
<211> 29
25 <212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence: Primer
30
<400> 146
cccaagcttg tcgacatgg gctggagcc 29

<210> 147
35 <211> 62
<212> DNA
<213> Artificial sequence

<220>
40 <223> Synthetic sequence: Primer

<400> 147

45 gagccggaag agctactacc cgatgaggaa gagaattcct tgatttcac cttggtcct 60
tg 62

Claims

- 50
1. An antibody conjugate for use in a method of treating rheumatoid arthritis in a patient, wherein the antibody conjugate comprises an antibody, or antigen-binding fragment thereof, which binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to a molecule having anti-inflammatory activity, wherein the antibody or antigen-binding fragment comprises a VH domain and a VL domain, wherein
55 said VH domain comprises a framework and a set of heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 83, 4 and 5, respectively; and
said VL domain comprises a framework and a set of light chain complementarity determining regions LCDR1, LCDR2

and LCDR3, wherein LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 86, 7 and 8, respectively.

- 5 **2.** An antibody conjugate for use in a method of delivering a molecule having anti-inflammatory activity to sites of rheumatoid arthritis in a patient, wherein the antibody conjugate comprises an antibody, or antigen-binding fragment thereof, which binds the Extra Domain-A (ED-A) of fibronectin and is conjugated to a molecule having anti-inflammatory activity, wherein the antibody or antigen-binding fragment comprises a VH domain and a VL domain, wherein said VH domain comprises a framework and a set of heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 83, 4 and 5, respectively; and
10 said VL domain comprises a framework and a set of light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 86, 7 and 8, respectively.
- 15 **3.** The antibody conjugate for use according to claim 1 or 2, wherein
- (a) said VH domain comprises:
- (i) the amino acid sequence of SEQ ID NO: 81; or
20 (ii) the amino acid sequence of SEQ ID NO: 81, wherein the amino acid at position 5 of SEQ ID NO: 81 is a leucine residue (L) rather than a valine residue (V); and
- b) said VL domain comprises:
- 25 (i) the amino acid sequence of SEQ ID NO: 82;
 (ii) the amino acid sequence of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K);
 (iii) amino acid residues 1-108 of SEQ ID NO: 82; or
 (iv) amino acid residues 1-108 of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82
30 is an arginine residue (R) rather than a lysine residue (K).
- 35 **4.** The antibody conjugate for use according to claim 3, wherein said VH domain comprises the amino acid sequence of SEQ ID NO: 81, wherein the amino acid at position 5 of SEQ ID NO: 81 is a leucine residue (L) rather than a valine residue (V); and said VL domain comprises amino acid residues 1-108 of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K).
- 40 **5.** The antibody conjugate for use according to any one of claims 1 to 4, wherein said antigen-binding fragment comprises a single chain Fv (scFv) or is a diabody.
- 45 **6.** The antibody conjugate for use according to any one of claims 1 to 5, wherein said antigen-binding fragment comprises a small immunoprotein (SIP).
- 7.** The antibody conjugate for use according to any one of claims 1 to 6, wherein said molecule having anti-inflammatory activity is IL-10.
- 8.** The antibody conjugate for use according to any one of claims 1 to 7, wherein said antibody or antigen-binding fragment is conjugated to said molecule having anti-inflammatory activity via a peptide linker.
- 50 **9.** The antibody conjugate for use according to claim 8, wherein said peptide linker comprises 15 amino acids and the amino acid sequence (SSSSG)₃.
- 10.** The antibody conjugate for use according to any one of claims 1 to 9, wherein said VH domain is joined to said VL domain via an amino acid linker.
- 55 **11.** The antibody conjugate for use according to claim 10, wherein said amino acid linker comprises 5 to 25 amino acids.
- 12.** The antibody conjugate for use according to claim 10, wherein said amino acid linker comprises 5 amino acids.

13. The antibody conjugate for use according to claim 1 or 2, wherein the antibody conjugate comprises:

(i) an antigen-binding fragment of an antibody which binds the Extra Domain A (ED-A) of fibronectin, wherein the antigen-binding fragment comprises a scFv or is a diabody, said antigen-binding fragment comprising:

a) a VH domain consisting of:

(i) the amino acid sequence of SEQ ID NO: 81; or

(ii) the amino acid sequence of SEQ ID NO: 81, wherein the amino acid at position 5 of SEQ ID NO: 81 is a leucine residue (L) rather than a valine residue (V); and

b) a VL domain consisting of:

(i) the amino acid sequence of SEQ ID NO: 82;

(ii) the amino acid sequence of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K);

(iii) amino acid residues 1-108 of SEQ ID NO: 82; or

(iv) amino acid residues 1-108 of SEQ ID NO: 82, wherein the amino acid at position 18 of SEQ ID NO: 82 is an arginine residue (R) rather than a lysine residue (K); and

wherein said VH domain is conjugated to said VL domain via a 5 amino acid linker; and

(ii) human interleukin-10 (IL-10),

wherein said VL domain of said antigen-binding fragment is conjugated to said human IL-10 via a peptide linker consisting of the amino acid sequence (SSSSG)₃.

14. The antibody conjugate for use according to any one claims 1-13, wherein said VH domain and/or said VL domain frameworks are human germline frameworks.

Patentansprüche

1. Antikörper-Konjugat zur Verwendung in einem Verfahren zur Behandlung rheumatoider Arthritis bei einem Patienten, wobei das Antikörper-Konjugat einen Antikörper oder ein Antigenbindungsfragment davon umfasst, der/das die Extra-Domain-A (ED-A) von Fibronectin bindet und an ein Molekül mit anti-inflammatorischer Aktivität konjugiert ist, wobei der Antikörper oder das Antigenbindungsfragment eine VH-Domäne und eine VL-Domäne umfasst, wobei die VH-Domäne ein Gerüst und einen Satz komplementaritätsbestimmender Regionen der schweren Kette HCDR1, HCDR2 und HCDR3 umfasst, wobei HCDR1, HCDR2 und HCDR3 die Aminosäuresequenzen von SEQ ID NOS: 83, 4 bzw. 5 umfassen; und die VL-Domäne ein Gerüst und einen Satz komplementaritätsbestimmender Regionen der leichten Kette LCDR1, LCDR2 und LCDR3 umfasst, wobei LCDR1, LCDR2 und LCDR3 die Aminosäuresequenzen von SEQ ID NOS: 86, 7 bzw. 8 umfassen.

2. Antikörper-Konjugat zur Verwendung in einem Verfahren zur Abgabe eines Moleküls mit anti-inflammatorischer Aktivität an Stellen mit rheumatoider Arthritis bei einem Patienten, wobei das Antikörper-Konjugat einen Antikörper oder ein Antigenbindungsfragment davon umfasst, der/das die Extra-Domain-A (ED-A) von Fibronectin bindet und an ein Molekül mit anti-inflammatorischer Aktivität konjugiert ist, wobei der Antikörper oder das Antigenbindungsfragment eine VH-Domäne und eine VL-Domäne umfasst, wobei die VH-Domäne ein Gerüst und einen Satz komplementaritätsbestimmender Regionen der schweren Kette HCDR1, HCDR2 und HCDR3 umfasst, wobei HCDR1, HCDR2 und HCDR3 die Aminosäuresequenzen von SEQ ID NOS: 83, 4 bzw. 5 umfassen; und die VL-Domäne ein Gerüst und einen Satz komplementaritätsbestimmender Regionen der leichten Kette LCDR1, LCDR2 und LCDR3 umfasst, wobei LCDR1, LCDR2 und LCDR3 die Aminosäuresequenzen von SEQ ID NOS: 86, 7 bzw. 8 umfassen.

3. Antikörper-Konjugat zur Verwendung gemäß Anspruch 1 oder 2, wobei

EP 3 281 952 B1

(a) die VH-Domäne umfasst:

- (i) die Aminosäuresequenz von SEQ ID NO: 81; oder
- (ii) die Aminosäuresequenz von SEQ ID NO: 81, wobei die Aminosäure an Position 5 von SEQ ID NO: 81 ein Leucinrest (L) statt ein Valinrest (V) ist; und

(b) die VL-Domäne umfasst:

- (i) die Aminosäuresequenz von SEQ ID NO: 82;
- (ii) die Aminosäuresequenz von SEQ ID NO: 82, wobei die Aminosäure an Position 18 von SEQ ID NO: 82 ein Argininrest (R) statt ein Lysinrest (K) ist;
- (iii) Aminosäurereste 1-108 von SEQ ID NO: 82; oder
- (iv) Aminosäurereste 1-108 von SEQ ID NO: 82, wobei die Aminosäure an Position 18 von SEQ ID NO: 82 ein Argininrest (R) statt ein Lysinrest (K) ist.

4. Antikörper-Konjugat zur Verwendung gemäß Anspruch 3, wobei die VH-Domäne die Aminosäuresequenz von SEQ ID NO: 81 umfasst, wobei die Aminosäure an Position 5 von SEQ ID NO: 81 ein Leucinrest (L) statt ein Valinrest (V) ist; und die VL-Domäne Aminosäurereste 1-108 von SEQ ID NO: 82 umfasst, wobei die Aminosäure an Position 18 von SEQ ID NO: 82 ein Argininrest (R) statt ein Lysinrest (K) ist.

5. Antikörper-Konjugat zur Verwendung gemäß einem der Ansprüche 1 bis 4, wobei das Antigenbindungsfragment ein Einzelketten-Fv (scFv) umfasst oder ein Diabody ist.

6. Antikörper-Konjugat zur Verwendung gemäß einem der Ansprüche 1 bis 5, wobei das Antigenbindungsfragment ein kleines Immunprotein (SIP) umfasst.

7. Antikörper-Konjugat zur Verwendung gemäß einem der Ansprüche 1 bis 6, wobei das Molekül mit anti-inflammatorischer Aktivität IL-10 ist.

8. Antikörper-Konjugat zur Verwendung gemäß einem der Ansprüche 1 bis 7, wobei der Antikörper oder das Antigenbindungsfragment über einen Peptidlinker an das Molekül mit anti-inflammatorischer Aktivität konjugiert ist.

9. Antikörper-Konjugat zur Verwendung gemäß Anspruch 8, wobei der Peptidlinker 15 Aminosäuren und die Aminosäuresequenz (SSSSG)₃ umfasst.

10. Antikörper-Konjugat zur Verwendung gemäß einem der Ansprüche 1 bis 9, wobei die VH-Domäne über einen Aminosäurelinker mit der VL-Domäne verbunden ist.

11. Antikörper-Konjugat zur Verwendung gemäß Anspruch 10, wobei der Aminosäurelinker 5 bis 25 Aminosäuren umfasst.

12. Antikörper-Konjugat zur Verwendung gemäß Anspruch 10, wobei der Aminosäurelinker 5 Aminosäuren umfasst.

13. Antikörper-Konjugat zur Verwendung gemäß Anspruch 1 oder 2, wobei das Antikörper-Konjugat umfasst:

(i) ein Antigenbindungsfragment eines Antikörpers, das die Extra-Domain-A (ED-A) von Fibronectin bindet, wobei das Antigenbindungsfragment ein scFv umfasst oder ein Diabody ist, wobei das Antigenbindungsfragment umfasst:

a) eine VH-Domäne, bestehend aus:

- (i) der Aminosäuresequenz von SEQ ID NO: 81; oder
- (ii) der Aminosäuresequenz von SEQ ID NO: 81, wobei die Aminosäure an Position 5 von SEQ ID NO: 81 ein Leucinrest (L) statt ein Valinrest (V) ist; und

b) eine VL-Domäne, bestehend aus:

- (i) der Aminosäuresequenz von SEQ ID NO: 82;

EP 3 281 952 B1

- (ii) der Aminosäuresequenz von SEQ ID NO: 82, wobei die Aminosäure an Position 18 von SEQ ID NO: 82 ein Arginingrest (R) statt ein Lysinrest (K) ist;
- (iii) Aminosäureresten 1-108 von SEQ ID NO: 82; oder
- (iv) Aminosäureresten 1-108 von SEQ ID NO: 82, wobei die Aminosäure an Position 18 von SEQ ID NO: 82 ein Arginingrest (R) statt ein Lysinrest (K) ist; und

wobei die VH-Domäne über einen 5-Aminosäurelinker an die VL-Domäne konjugiert ist; und (ii) humanes Interleukin-10 (IL-10),

wobei die VL-Domäne des Antigenbindungsfragments über einen Peptidlinker, bestehend aus der Aminosäuresequenz (SSSSG)₃, an das humane IL-10 konjugiert ist.

14. Antikörper-Konjugat zur Verwendung gemäß einem der Ansprüche 1-13, wobei die VH-Domänen- und/oder die VL-Domänen-Gerüste humane Keimbahn-Gerüste sind.

Revendications

1. Conjugué d'anticorps pour une utilisation dans un procédé de traitement de la polyarthrite rhumatoïde chez un patient, dans lequel le conjugué d'anticorps comprend un anticorps, ou un fragment de liaison aux antigènes de celui-ci, qui se lie à l'extra-domaine A (ED-A) de fibronectine et est conjugué à une molécule ayant une activité anti-inflammatoire, dans lequel l'anticorps ou le fragment de liaison aux antigènes comprend un domaine VH et un domaine VL, dans lequel

ledit domaine VH comprend une charpente et une série de régions de détermination de la complémentarité de la chaîne lourde HCDR1, HCDR2 et HCDR3, dans lequel HCDR1, HCDR2 et HCDR3 comprennent les séquences d'acides aminés de SEQ ID N° : 83, 4 et 5, respectivement ; et

ledit domaine VL comprend une charpente et une série de régions de détermination de la complémentarité de la chaîne légère LCDR1, LCDR2 et LCDR3, dans lequel LCDR1, LCDR2 et LCDR3 comprennent les séquences d'acides aminés de SEQ ID N° : 86, 7 et 8, respectivement.

2. Conjugué d'anticorps pour une utilisation dans un procédé de délivrance d'une molécule ayant une activité anti-inflammatoire à des sites de polyarthrite rhumatoïde chez un patient, dans lequel le conjugué d'anticorps comprend un anticorps, ou un fragment de liaison aux antigènes de celui-ci, qui se lie à l'extra-domaine A (ED-A) de fibronectine et est conjugué à une molécule ayant une activité anti-inflammatoire, dans lequel l'anticorps ou le fragment de liaison aux antigènes comprend un domaine VH et un domaine VL, dans lequel

ledit domaine VH comprend une charpente et une série de régions de détermination de la complémentarité de la chaîne lourde HCDR1, HCDR2 et HCDR3, dans lequel HCDR1, HCDR2 et HCDR3 comprennent les séquences d'acides aminés de SEQ ID N° : 83, 4 et 5, respectivement ; et

ledit domaine VL comprend une charpente et une série de régions de détermination de la complémentarité de la chaîne légère LCDR1, LCDR2 et LCDR3, dans lequel LCDR1, LCDR2 et LCDR3 comprennent les séquences d'acides aminés de SEQ ID N° : 86, 7 et 8, respectivement.

3. Conjugué d'anticorps pour une utilisation selon la revendication 1 ou 2, dans lequel

(a) ledit domaine VH comprend :

(i) la séquence d'acides aminés de SEQ ID N° : 81 ; ou

(ii) la séquence d'acides aminés de SEQ ID N° : 81, dans lequel l'acide aminé à la position 5 de la SEQ ID N° : 81 est un résidu de leucine (L) plutôt qu'un résidu de valine (V) ; et

(b) ledit domaine VL comprend :

(i) la séquence d'acides aminés de SEQ ID N° : 82 ;

(ii) la séquence d'acides aminés de SEQ ID N° : 82, dans lequel l'acide aminé à la position 18 de la SEQ ID N° : 82 est un résidu d'arginine (R) plutôt qu'un résidu de lysine (K) ;

(iii) les résidus d'acides aminés 1 à 108 de la SEQ ID N° : 82 ; ou

(iv) les résidus d'acides aminés 1 à 108 de la SEQ ID N° : 82, dans lequel l'acide aminé à la position 18 de la SEQ ID N° : 82 est un résidu d'arginine (R) plutôt qu'un résidu de lysine (K).

EP 3 281 952 B1

4. Conjugué d'anticorps pour une utilisation selon la revendication 3, dans lequel ledit domaine VH comprend la séquence d'acides aminés de SEQ ID N° : 81, dans lequel l'acide aminé à la position 5 de la SEQ ID N° : 81 est un résidu de leucine (L) plutôt qu'un résidu de valine (V) ; et ledit domaine VL comprend les résidus d'acides aminés 1 à 108 de la SEQ ID N° : 82, dans lequel l'acide aminé à la position 18 de la SEQ ID N° : 82 est un résidu d'arginine (R) plutôt qu'un résidu de lysine (K).
- 5
5. Conjugué d'anticorps pour une utilisation selon l'une des revendications 1 à 4, dans lequel ledit fragment de liaison aux antigènes comprend une chaîne unique Fv (scFv) ou est un diabody.
- 10
6. Conjugué d'anticorps pour une utilisation selon l'une des revendications 1 à 5, dans lequel ledit fragment de liaison aux antigènes comprend une petite immunoprotéine (SIP).
- 15
7. Conjugué d'anticorps pour une utilisation selon l'une des revendications 1 à 6, dans lequel ladite molécule ayant une activité anti-inflammatoire est IL-10.
8. Conjugué d'anticorps pour une utilisation selon l'une des revendications 1 à 7, dans lequel ledit anticorps ou fragment de liaison aux antigènes est conjugué à ladite molécule ayant une activité anti-inflammatoire au moyen d'un lieu peptidique.
- 20
9. Conjugué d'anticorps pour une utilisation selon la revendication 8, dans lequel ledit lieu peptidique comprend 15 acides aminés et la séquence d'acides aminés (SSSSG)₃.
- 25
10. Conjugué d'anticorps pour une utilisation selon l'une des revendications 1 à 9, dans lequel ledit domaine VH est joint audit domaine VL au moyen d'un lieu d'acides aminés.
- 30
11. Conjugué d'anticorps pour une utilisation selon la revendication 10, dans lequel ledit lieu d'acides aminés comprend 5 à 25 acides aminés.
- 35
12. Conjugué d'anticorps pour une utilisation selon la revendication 10, dans lequel ledit lieu d'acides aminés comprend 5 acides aminés.
- 40
13. Conjugué d'anticorps pour une utilisation selon la revendication 1 ou 2, dans lequel le conjugué d'anticorps comprend :
- (i) un fragment de liaison aux antigènes d'un anticorps qui se lie à l'extra-domaine A (ED-A) de fibronectine, dans lequel le fragment de liaison aux antigènes comprend une scFv ou est un diabody, ledit fragment de liaison aux antigènes comprenant :
- (a) un domaine VH constitué par :
- (i) la séquence d'acides aminés de SEQ ID N° : 81 ; ou
- (ii) la séquence d'acides aminés de SEQ ID N° : 81, dans lequel l'acide aminé à la position 5 de la SEQ ID N° : 81 est un résidu de leucine (L) plutôt qu'un résidu de valine (V) ; et
- (b) un domaine VL constitué par :
- (i) la séquence d'acides aminés de SEQ ID N° : 82 ;
- (ii) la séquence d'acides aminés de SEQ ID N° : 82, dans lequel l'acide aminé à la position 18 de la SEQ ID N° : 82 est un résidu d'arginine (R) plutôt qu'un résidu de lysine (K) ;
- (iii) les résidus d'acides aminés 1 à 108 de la SEQ ID N° : 82 ; ou
- (iv) les résidus d'acides aminés 1 à 108 de la SEQ ID N° : 82, dans lequel l'acide aminé à la position 18 de la SEQ ID N° : 82 est un résidu d'arginine (R) plutôt qu'un résidu de lysine (K) ; et
- dans lequel ledit domaine VH est conjugué audit domaine VL au moyen d'un lieu de 5 acides aminés ; et
- (ii) l'interleukine-10 (IL-10) humaine,
- dans lequel ledit domaine VL dudit fragment de liaison aux antigènes est conjugué à ladite IL-10 humaine au moyen

EP 3 281 952 B1

d'un lieur peptidique constitué par la séquence d'acides aminés (SSSSG)₃.

14. Conjugué d'anticorps pour une utilisation selon l'une des revendications 1 à 13, dans lequel lesdites charpentes de domaine VH et/ou de domaine VL sont des charpentes de lignée germinale humaine.

5

10

15

20

25

30

35

40

45

50

55




Figure 1




Figure 2

Figure 3

89

A 1 NIDRPKGLAFTD VD VDSIKIAWESPQQVSR YRVTYSSPEDG IHELFPAPDGEEDTAE LQ

B 1 NIDRPKGLAFTD VD VDSIKIAWESPQQVSR YRVTYSSPEDG IRELFPAPDGEDDTAE LQ

A 61 GLRPGSEYTVSVVALHDDMESQPLIGTQST

B 61 GLRPGSEYTVSVVALHDDMESQPLIGIQST

Figure 4A

GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTG
GGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTT
TAGCCCGCGGAGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAG
GGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCA
CATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAG
AGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTG
AGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAAGTACTC
ATTTGTATCTTTTTGACTACTGGGGCCAGGGAACCCTGGTCAC
CGTCTCGAGT

Figure 4B

GGCGGTGGAGGTTCTGGCGGCGGTGGCAGTGGCGGTGGAGGTT
CCGGGGGTGGAGGATCT

Figure 4C

GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTC
CAGGGGAAAAAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGT
TAGCTCTGCGTGGTTAGCCTGGTACCAGCAGAAACCTGGCCAG
GCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTG
GCATCCCAGACAGGTTTCAGTGGCAGTGGGTCTGGGACAGACTT
CACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTG
TATTACTGTCAGCAGATGCGTGGTCGGCCGCCGACGTTCCGGCC
AAGGGACCAAGGTGGAAATCAAAGCGGCCGCAGAACAAAAACT
CATCTCAGAAGAGGATCTGAATGGGGCCGCATAGACTGTGAAA

Figure 5A

EVQLVESGGGLVQPGGSLRLSCAASGFTFSPRRMSWVRQ
APGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNT
LYLQMNSLRAEDTAVYYCAKSTHLYLFDYWGQGTLVTVS
S

Figure 5B

GGGGSGGGGSGGGGSGGGGS

Figure 5C

EIVLTQSPGTL~~SL~~SPGEKATLSCRASQSVSSSAWLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR
LEPEDFAVYYCQQMRGRPPTFGQGTKVEIKAAAEQKLIS
EEDLNGAA


Figure 6

AAGCTTGTGCGACCATGGGCTGGAGCCTGATCCTCCTGTTCCCTCGTCGCTGTGG
CTACAGGTAAGGGGCTCACAGTAGCAGGCTTGAGGTCTGGACATATATATGGG
TGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTGCACTCGGAGGTGCA
GCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC
TCCTGTGCAGCCTCTGGATTCACCTTTAGCCTGTTTACGATGAGCTGGGTCCG
CCAGGCTCCAGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGT
GGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAG
ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGA
CACGGCCGTATATTACTGTGCGAAAAGTACTCATTTGTATCTTTTTGACTACTG
GGCCAGGGAACCCTGGTCACCGTCTCGAGTggtggaggcggttcaggcgagggtggc
tctggcggtggcggaGAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCT
CCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCATGC
CGTTTTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCAT
CTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTTCAGTGGCAGT
GGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATT
TTGCAGTGTATTACTGTCAGCAGATGCGTGGTCCGCCGCCGACGTTCCGGCCA
AGGGACCAAGGTGGAAATCAAAGAATTCTCTTCCTCATCGGGTAGTAGCTCTT
CCGGCTCATCGTCCAGCGGCAGCCCAGGGCCAGGGCACCCAGTCTGAGAACAG
CTGCACCCACTTCCCAGGCAACCTGCCTAACATGCTTCGAGATCTCCGAGATG
CCTTCAGCAGAGTGAAGACTTTCTTTCAAATGAAGGATCAGCTGGACAACCTTGT
TGTTAAAGGAGTCCTTGCTGGAGGACTTTAAGGGTTACCTGGGTTGCCAAGCCT
TGTCTGAGATGATCCAGTTTTACCTGGAGGAGGTGATGCCCAAGCTGAGAAC
CAAGACCCAGACATCAAGGCGCATGTGAACTCCCTGGGGGAGAACCTGAAGAC
CCTCAGGCTGAGGCTACGGCGCTGTCATCGATTTCTTCCCTGTGAAAACAAGA
GCAAGGCCGTGGAGCAGGTGAAGAATGCCTTTAATAAGCTCCAAGAGAAAGGC
ATCTACAAAGCCATGAGTGAGTTTGACATCTTCATCAACTACATAGAAGCCTACA
TGACAATGAAGATACGAAACtaatgaGCGGCCGC

Figure 7

EVQLLESGGG LVQPGGSLRL SCAASGFTFS LFTMSWVRQA PGKGLEWVSA
 ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKST
 HLYLFDYWGQ GTLVTVssgg ggsrgggsgg ggEIVLTQSP GTLSLSPGER
 ATLSCRASQS VSMPFLAWYQ QKPGQAPRLI IYGASSRATG IPDRFSGSGS
 GTDFTLTISR LEPEDFAVYY CQQMRGRPPT FGQGTKVEIK *Efssssgsss*
*sgsssg*SPG QGTQSENSCT HFPGNLPNML RDLRDAFSRV KTFQMKDQL
DNLLKESLL EDFKGYLGCQ ALSEMIQFYL EEVMPQAENQ DPDIKAHVNS
LGENLKTLLR RLRRCHRFLP CENKSKAVEQ VKNAFNKLQE KGIYKAMSEF
DIFINYIEAY MTMKIRN

Figure 8



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- EP 2007004044 W, Trachsel [0008]
- WO 2006050834 A [0040]
- WO 0034784 A [0047]
- EP 184187 A [0052]
- GB 2188638 A [0052]
- EP 239400 A [0052]
- EP 0120694 A [0053]
- EP 0125023 A [0053]
- WO 9201047 A [0054] [0074] [0085] [0092]
- US 5969108 A [0054] [0074]
- US 5565332 A [0054] [0074]
- US 5733743 A [0054] [0074]
- US 5858657 A [0054] [0074]
- US 5871907 A [0054] [0074]
- US 5872215 A [0054] [0074]
- US 5885793 A [0054] [0074]
- US 5962255 A [0054] [0074]
- US 6140471 A [0054] [0074]
- US 6172197 B [0054] [0074]
- US 6225447 B [0054] [0074]
- US 6291650 B [0054] [0074]
- US 6492160 B [0054] [0074]
- US 6521404 B [0054] [0074]
- US 9209965 W [0056]
- WO 9413804 A [0056] [0063]
- WO 0246455 A [0074]
- WO 0162298 A [0103]
- US 60983606 B [0204]

Non-patent literature cited in the description

- **KORNBLIHTT et al.** *Nucleic Acids Res.*, 1984, vol. 12, 5853-5868 [0041] [0203]
- **PAOLELLA et al.** *Nucleic Acids Res.*, 1988, vol. 16, 3545-3557 [0041] [0203]
- **BORSI et al.** *J. Cell Biol.*, 1987, vol. 104, 595-600 [0043]
- **GIOVANNONI.** *Nucleic. Acid Research*, 2001, vol. 29 (5), E27 [0154] [0203]
- **AMIT et al.** *Science*, 1986, vol. 233, 747-753 [0203]
- **ANDERSEN et al.** *Current Opinion in Biotechnology*, 2002, vol. 13, 117 [0203]
- **AUSUBEL et al.** Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology. John Wiley & Sons, 1999 [0203]
- **BAGSHAW K.D. et al.** *Antibody, Immunoconjugates and Radiopharmaceuticals*, 1991, vol. 4, 915-922 [0203]
- **BALZA et al.** *FEBS Lett.*, 1988, vol. 228, 42-44 [0203]
- **BATISTA et al.** *J. Exp. Med.*, 1996, vol. 184, 2197-205 [0203]
- **BERNDT et al.** *Histochem Cell Biol*, 1998, vol. 109 (3), 249-255 [0203]
- **BIRCHLER et al.** *J. Immunol. Methods*, 1999, vol. 231, 239-248 [0203]
- **BIRD et al.** *Science*, 1988, vol. 242, 423-426 [0203]
- **BORSI et al.** *J. Cell. Biol.*, 1987, vol. 104, 595-600 [0203]
- **BORSI et al.** *FEBS Lett.*, 1990, vol. 261, 175-178 [0203]
- **BORSI et al.** *J. Biol.Chem.*, 1995, vol. 270, 6243-6245 [0203]
- **BORSI et al.** *Exp. Cell Res.*, 1998, vol. 240, 244-251 [0203]
- **BORSI et al.** *Int J Cancer*, 2000, vol. 102 (1), 75-85 [0203]
- **BRACK et al.** *Clin. Cancer Res.*, 2006, vol. 12, 3200-3208 [0203]
- **CARNEMOLLA et al.** *J. Cell. Biol.*, 1989, vol. 108, 1139-1148 [0203]
- **CATON et al.** *J. Immunol.*, 1990, vol. 144, 1965-1968 [0203]
- **CHADD et al.** *Current Opinion in Biotechnology*, 2001, vol. 12, 188-194 [0203]
- **CHOTHIA et al.** *J. Mol. Biol.*, 1987, vol. 196, 901-917 [0203]
- **CHOTHIA et al.** *Nature*, 1989, vol. 342, 877-883 [0203]
- **COURTNEY et al.** *Nature*, 1980, vol. 283 (5748), 666-8 [0203]
- **DEVOS et al.** *Nucl. Acids Res.*, 1983, vol. 11, 4307-4323 [0203]
- **FFRENCH-CONSTANT.** *Exp. Cell Res.*, 1995, vol. 221, 261-271 [0203]
- **GLENNIE M J et al.** *J. Immunol.*, 1987, vol. 139, 2367-2375 [0203]
- **HAAN et al.** *BioCentury*, 2004, vol. 12 (5), A1-A6 [0203]
- **HANAHAN et al.** *Cell*, 2000, vol. 100, 57-70 [0203]
- **HARLOW ; LANE.** *Antibodies: A Laboratory Manual.* Cold Spring Harbor Laboratory, 1988, 726 [0203]

- **HEIKINHEIMO et al.** *Virchows Arch. B Cell Pathol. Incl. Mol. Pathol.*, 1991, vol. 61, 101-109 [0203]
- **HOLLIGER ; BOHLEN.** *Cancer and metastasis*, 1999, vol. 18, 411-419 [0203]
- **HOLLIGER et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0203]
- **HOLLIGER et al.** *Current Opinion Biotechnol*, 1993, vol. 4, 446-449 [0203]
- **HOLT et al.** *Trends in Biotechnology*, 2003, vol. 21, 484-490 [0203]
- **HOOGENBOOM et al.** *Nucleic Acids Res.*, 1991, vol. 19 (15), 4133-7 [0203]
- **HU et al.** *Cancer Res.*, 1996, vol. 56, 3055-3061 [0203]
- **HUSTON et al.** *PNAS USA*, 1988, vol. 85, 5879-5883 [0203]
- **HYNES, R.O.** *Fibronectins*. Springer-Verlag, 1990 [0203]
- **JACOBS et al.** *Hum. Pathol.*, 2002, vol. 33, 29-38 [0203]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. US Department of Health and Human Services, 1987 [0203]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. US Department of Health and Human Services, Public Service, 1991 [0203]
- **KABAT et al.** *J. Immunol.*, 1991, vol. 147, 1709-1719 [0203]
- **KASPAR et al.** *Int. J. Cancer*, 2006, vol. 118, 1331-1339 [0203]
- **KNAPPIK et al.** *J. Mol. Biol.*, 2000, vol. 296, 57-86 [0203]
- **KOCH et al.** *Ann Rheum Dis*, 2003, vol. 62 (2), 60-67 [0203]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-497 [0203]
- **KOIDE et al.** *Journal of Molecular Biology*, 1998, vol. 284, 1141-1151 [0203]
- **KONTERMANN et al.** S, *Antibody Engineering*. Springer-Verlag New York, 2001 [0203]
- **KOUKOULIS et al.** *J. Submicrosc. Cytol. Pathol.*, 1993, vol. 25, 285-295 [0203]
- **KOUKOULIS et al.** *Ultrastruct. Pathol.*, 1995, vol. 19, 37-43 [0203]
- **KREBS et al.** *Journal of Immunological Methods*, 2001, vol. 254, 67-84 [0203]
- **KRIEGSMANN et al.** *Rheumatol Int*, 2004, vol. 24 (1), 25-33 [0203]
- **LARRICK JW ; THOMAS DW.** *Current Opinion in Biotechnology*, 2001, vol. 12, 411-418 [0203]
- **LEDERMANN J.A. et al.** *Int. J. Cancer*, 1991, vol. 47, 659-664 [0203]
- **LI et al.** *Protein Engineering*, 1997, vol. 10, 731-736 [0203]
- **LOHI et al.** *Int. J. Cancer*, 1995, vol. 63, 442-449 [0203]
- **MAEDA et al.** *Biochem. Biophys. Res. Comm.*, 1983, vol. 115, 1040-1047 [0203]
- **MATSUMOTO et al.** *Jpn. J. Cancer Res.*, 1999, vol. 90, 320-325 [0203]
- **MCCAFFERTY et al.** *Nature*, 1990, vol. 348, 552-554 [0203]
- **MENDEZ, M. et al.** *Nature Genet*, 1997, vol. 15 (2), 146-156 [0203]
- **MERCHAND et al.** *Nature Biotech.*, 1998, vol. 16, 677-681 [0203]
- **NERI, D. ; BICKNELL, R.** *Nat Rev Cancer*, 2005, vol. 5, 436-446 [0203]
- **NYGREN et al.** *Current Opinion in Structural Biology*, 1997, vol. 7, 463-469 [0203]
- **OYAMA et al.** *J. Biol. Chem.*, 1989, vol. 264, 10331-10334 [0203]
- **PINI et al.** *J. Biol. Chem.*, 1998, vol. 273, 21769-21776 [0203]
- **PLUCKTHUN.** *Bio/Technology*, 1991, vol. 9, 545-551 [0203]
- **REITER et al.** *Nature Biotech*, 1996, vol. 14, 1239-1245 [0203]
- **REPP et al.** *J. Hemat.*, 1995, 377-382 [0203]
- **RIDGEWAY et al.** *Protein Eng.*, 1996, vol. 9, 616-621 [0203]
- Sustained and Controlled Release Drug Delivery Systems. Marcel Dekker, Inc, 1978 [0203]
- **ROESLI et al.** *Nature Protocols*, 2006, vol. 1, 192-199 [0203]
- **RUF et al.** *J. Biol. Chem.*, 1991, vol. 266, 15719-15725 [0203]
- **RYBAK et al.** *Nat. Methods*, 2005, vol. 2, 291-298 [0203]
- **RYBAK et al.** *ChemMedChem*, 2006, vol. 2, 22-40 [0203]
- **SAMBROOK ; RUSSELL.** *Molecular Cloning: a Laboratory Manual*. Cold Spring Harbor Laboratory Press, 2001 [0203]
- **SCARPATI et al.** *Biochemistry*, 1987, vol. 26, 5234-5238 [0203]
- **SCARPINO et al.** *J. Pathol.*, 1999, vol. 188, 163-167 [0203]
- **SCHEURER et al.** *Proteomics*, 2005, vol. 5, 3035-3039 [0203]
- **SEGAL et al.** *PNAS*, 1974, vol. 71, 4298-4302 [0203]
- **SHARON et al.** *PNAS*, 1990, vol. 87, 4814-4817 [0203]
- **SHARON et al.** *J. Immunol.*, 1990, vol. 144, 4863-4869 [0203]
- **SILACCI et al.** *Proteomics*, 2003, vol. 5, 2340-2350 [0203]
- **STAERZU. D. ; BEVAN M. J.** *PNAS*, 1986, 83 [0203]
- **SURESH et al.** *Method Enzymol.*, 1986, vol. 121, 210-228 [0203]
- **TANIGUCHI et al.** *Nature*, 1983, vol. 302, 305-310 [0203]
- **TARLI et al.** *Blood*, 1999, vol. 94 (1), 192-198 [0203]
- **TAVIAN et al.** *Int. J. Cancer*, 1994, vol. 56, 820-825 [0203]

EP 3 281 952 B1

- **TAYLOR.** *Arthritis Res*, 2002, vol. 4 (3), 99-107 [0203]
- **TERRANA et al.** *Cancer Res.*, 1987, vol. 47, 3791-3797 [0203]
- **THOMPSON et al.** *J Exp Med*, 1991, vol. 173, 507-510 [0203]
- **THORPE.** *Clin. Cancer Res.*, 2004, vol. 10, 415-427 [0203]
- **TRACHSEL et al.** *Adv. Drug Deliv. Rev.*, 2006, vol. 58, 735-754 [0203]
- **TRACHSEL et al.** *Arthritis Res Ther*, 2007, vol. 9 (1), R9 [0203]
- **VITI et al.** *Methods Enzymol.*, 2000, vol. 326, 480-505 [0203]
- **WALSH et al.** *Am J Pathol*, 1998, vol. 152 (3), 691-702 [0203]
- **WARD et al.** *Nature*, 1989, vol. 341, 544-546 [0203]
- *BioCentury, The Bernstein Report on BioBusiness*, 2004, vol. 12 (42), A1-A7 [0203]